treatment_name,liquid_available,odt_available,first_author,doi,commercial_affiliation,publication_date,journal,study_type,duration,sample_size,gender_ratio,age_range,dose_range,primary_outcome_area,primary_outcome_measures,primary_results,secondary_outcome_area,secondary_outcome_measures,secondary_results,side_effects,safety_rating,dropout_rate,race_ethnicity,notes,sequence_generation_bias,allocation_concealment_bias,outcome_assessor_blinding_bias,clinician_blinding_bias,attrition_bias,reporting_bias,bias_notes
Anodal transcranial direct current stimulation (tDCS),,,"Amatachaya, Anuwat",10.1155/2014/173073,No conflicts of interest. ,October 2014,Behavioural Neurology,Randomized Double-blind Placebo Controlled ,"8 weeks total (5 consecutive days tDCS, 1 week assessment, 4-week washout, 5 consecutive days days of tDCS)",20,100% M,5-8 y,"1mA anodal tDCS targeting left dorsolateral prefrontal cortex (DLPFC), or sham (placebo) tDCS",,"CARS, ATEC, CGAS, CGI-I","Greater pre to posttreatment decrease in CARS score that was maintained for 7 days post treatment (end of trial). Significant improvement CGI-I in the tDCS compared to sham group. Significant change in in total ATEC, health and behavioral problems, sociability, and sensory/cognitive awareness. No change in language ATEC. Statistical increase in CGAS in the active group compared to the sham group. ",Adverse effects,,,No AEs in either group,,,Not reported,Results of this study are not explained very clearly. ,low risk - Computer generated randomization in 1:1 ratio in blocks of four randomizations.,"Unclear risk - The tDCS was masked by opaque cover during stimulation. Power indicator was lit up during active and sham stimulation. ""However, in sham simulation the current was discontinued after 30 seconds while the power indicator remained.""","Unclear risk - The authors state the trial was ""double blinded"", but do not specify who was blinded.","Unclear risk - The authors state the trial was ""double blinded"", but do not specify who was blinded.","High risk - Statistical data on rates of adverse effects was not provided. CGI-severity baseline scores provided, but no endpoint scores. ","Unclear risk - Authors state that there were no adverse effects, but do not include data for this. ",
Arbaclofen,Yes,No,"Veenstra-VanderWeele, Jeremy",10.1038/npp.2016.237,"Seaside Therapeutics, Roche, Novartis, SynapDx, Forest, Springer and wiley. ","November 9, 2016",Neuropsychopharmacology,Randomized Double-blind Placebo Controlled  ,12 weeks ,150,124 M: 26 F,5-21 y; mean: 11 y,,Social behaviors. ,ABC-C Social withdrawal/Lethargy,No significant difference between the arbaclofen and placebo tx groups. ,"Social behaviors, irritability, anxiety, attention/hyperactivity. ","CGI-I, CGI-S, Vineland-II Socialization, Visual Analog Scale-Anxiety and Disruptive, ADHD-IV. Exploratory measures: ABC-C (all subscales), Parenting stress Index, Vineland-II Maldaptive behavior and communication, CSHQ-Total & Daytime sleepiness, Sensory Profile Score",There was improvement on the CGI of Severity and greater improvement on the Vineland Adaptive Behavior Scales II socialization domain in the arbaclofen treatment group.,"Generally well tolerated. Side effects that led to discontinuation were suicidal ideation, aggression, emotional distress, sleep disorder, oculogyric crisis, dyskinesia, heaviness, and rash. ","10 participants withdrew due to AEs. There was an instance of suicidal ideation in the arbaclofen treatment group, which led to discontinuation of drug. ","n=20 (15 Arbaclofen, 5 Placebo)",96 White Non-Hispanic; 19 White Hispanic; 17 African American; 8 Asian; 10 Other,,Low risk - centrally generated randomization list,Low Risk - Identical oral disintegrating tablets of arbaclofen or placebo. The titration schedule was the same for placebo and arbaclofen.,,Unclear risk ,Low risk - All data reported. ,"Low risk - All outcome measures were reported, even insignificant findings. Serious adverse effects were stated and dropouts due to adverse effects were also noted. ","Three authors received research funding and have consulted for seaside therapeutics. MC, KW-B, PPW, and RLC were employees of Seaside Therapeutics at the time of the study. MFB and RLC wre co-founders of Seaside Therapeutics. "
Arbaclofen (STX209),Yes,No,"Delahunty, C",,,2013,American Academy of Pediatrics,RCT - Phase 2,12 weeks ,150,124 M: 26 F,5-21 y,"max: 10 mg 3x/d for 5-11y, 15 mg 3x/d for 12-21 y",Social behaviors. ,ABC lethargy/social withdrawal,No significant improvement with treatment. ,Autism severity and social behaviors,"CGIS severity and improvement, Socialization & Communication scales of VABS","CGIS severity improved more in the arbaclofen group. Other outcome measures showed no improvement, except for the VABS socialization subscale in 'higher functioning' patients. ","Well tolerated. Aggression, somnolence, sleep disturbances. ",1 serious AE in arbaclofen group (suicidal ideation). ,n=20,,,,,,,,,
Arbaclofen (STX209),Yes,No,"Berry-Kravis, EM",10.1126/scitranslmed.3004214,No conflicts of interest,2012,Science Translational Medicine,Randomized Double-blind Placebo Controlled  - Pilot,15 months,63,55 M: 8 F,6-39 y,"max: 10 mg BID for children, 10 mg 3x/d for adults",Irritability in fragile x syndrome (FXS),ABC-irritability,No significant improvement in ABC scores with treatment. ,Neurobehavioral function in FXS,"CGIS, ABC, VABS, SRS, Repetitive Behavior Scale-revised, Child and Adolescent Symptom inventory Anxiety scale, ADHD Rating Scale-IV, VAS, vocabulary and short term/working memory",VAS problem behavior rating scores were better during arbaclofen treatment. Social avoidance (ABC) improved significantly more during arbaclofen treatment. Participants with the most severe social impairments improved more on the VABS socialization scale and the CGIS.  ,Well tolerated. Sedation and headache. ,Generally safe,,,,,,,,,,
Aripiprazole,Yes ,"Yes (vanilla, peppermint)","Ichikawa, Hironobu",10.1007/s10578-016-0704-x,3 authors are Employees of Otsuka Pharmaceutical Co. ,"December 21, 2016",Child Psychiatry and Human Development,Randomized Double-blind Placebo Controlled  ,8 weeks,92,17 F: 75 M,6-17 y; mean: 10 y,1-15 mg/d; Mean: 8.1 mg/d (SD: 2.0),Irritability,Caregiver-rated ABC-I irritability subscale score ,Flexible dose aripiprazole is shown to reduce varying symptoms of irritability in children with ASD-- as measured by ABC-I. ,,"Clinical Global Impressions-Improvement (CGI-I Score), other ABC-J subscales, CGI-S, CGAS, and Y-BOCS.",Aripiprazole can improve clinician-rated CGI-I scores in children with ASD. ,Well tolerated with no serious AEs. Somnolence in 24 patients treated w/ the medication. Serious heat disorder in patient receiving the placebo. ,"Generally safe. Vital signs, body weight, and C-SSRS collected at every visit ",0% Aripiprazole; 6.7% Placebo,Conducted with 'specific populations considering influence of genetic/physiologic variation and/or cultural environmental difference on treatment variable'. ,"This study was conducted to test the effects of aripiprazole treatment in Japanese children, as all studies of this drug had used primarily caucasion populations in the U.S. ",Low risk - Computer generated at central location.,Unclear risk - Not reported. ,Unclear risk - ,Low risk - Participants and clinicians were blinded to the treatment allocation,Low risk - All data reported ,"Low risk - All data reported, including insignificant results. ",
Aripiprazole,Yes,"Yes (vanilla, peppermint)","Findling, Robert",,"Conflicts of interest. Affiliations with: Kennedy Krieger Institute, Johns Hopkins University, Bristol-Meyers Squibb (9/10 Authors), Otsuka Pharmaceutical Co, Genzyme Corp",January 2014,Journal of Clinical Psychiatry,Randomized placebo controlled relapse prevention trial,42 Weeks (Phase 1: 13-26 weeks; Phase 2: 16 weeks),85,17 F: 68 M,6-17 y; Mean: 10 y,"2-15 mg/d, flexible dose; Mean dose: ",,Relapse time during maitenance therapy. ,"The difference in time to relapse between aripiprozole and placebo, during maintenance therapy, was not statistically significant. ",Irritability. ,Clinical Global Impressions-Improvement (CGI-I) and Aberrant Behavior Checklist (ABC-I Scores),No significant difference in the mean change in CGI-I and ABC-I scores. ,"Mild side effects. Common side effects included weight gain, somnolence, vomiting, upper respiratory tract infection, constipation, and movement disorder. ",No serious adverse effects. 80% of patients had mild AEs. EPS observed in 7.7% of the treatment group. ,46% Aripiprazole; 57% Placebo ,69.4% white; 22.4% black;                           3% Asian; 1% American Indian/Alaska Native;                                        13% other,"9/10 authors associated with Otsuka Pharmaceuticals and Bristol-Myers Squibb, both of which are primary shareholders in Abilify. ",,,,,,,
Aripiprazole,Yes,"Yes (vanilla, peppermint)","Marcus, Ronald N. ",,Several authors are affiliated with Otsuka Pharmaceutical Development and Bristol-Myers Squibb. ,November 2009,The American Journal of Child Adolescent Psychiatry,RPCT Fixed-Dose l ,8 Weeks,218,195 M,6-17 y; Mean: 9.7 y,"5, 10, or 15 mg/d",Irritability,Aberrant Behavior Checklist-Irritability subscale (ABC-I) Scores,"""Aripiprazole was effective at reducing irritability in children and adolescents"". The mean ABC-I score for the groups treated with Aripiprazole was significantly lower at week 8 than the placebo group. ",,Clinical Global Impressions-Improvement (CGI-I) Scores ,"Participants treated with Aripiprazole ""demonstrated significantly greater improvements in mean Clinical Global Impressions-Improvement score than placebo at week 8"".",Well tolerated. The most common adverse event was sedation. ,"Generally safe. Two serious adverse events. Presyncope at 5 mg/d, and Aggression at 10 mg/d. ",Drop out rate: 18%; Placebo (n=14); Aripiprazole 5mg (n=9); Aripiprazole 10mg (n=10); Aripiprazole 15mg (n=7),155 White; 50 Black; 6 Asian; 7 Other,,,,,,,,
Aripiprazole,Yes,"Yes (vanilla, peppermint)","Owen, Randall",10.1542/peds.2008-3782,Funding provided by Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co. ,December 2009,American Academy of Pediatrics,Randomized Double-blind Placebo Controlled  ,8 weeks,98,86 M: 12 F,6-17 y; Mean: 8.8-9.7 y,"Flexible dose: 5, 10, or 15 mg/d",Irritability,Caregiver rated ABC-irritability subscale,"""Aripiprazole was significantly more efficacious than placebo at treating irrtability� on the caregiver-rated ABC irritability subscale.""","Hyperactivity, stereotypy, inappropriate speech. Quality of life.","CGI-I; ABC- hyperactivity, stereotypy, inappropriate speech, and lethargy/social withdrawal; YBOCS; PedsQL; response rate; and CGSQ","Significant improvements over placebo on CGI-I scores. Positive results on the ABC hyperactivity, stereotypy, and inappropriate speech subscales. Greater improvement in PedsQL and CGSQ scales. ","Generally well tolerated. 91.5% of aripiprazole pts had treatment emergent Aes. Most common side effects included weight gain, fatigue, somnolence, and vomiting. ",No serious adverse events. ,n=23 (n=Aripiprazole- 5 due to AEs),73 White; 18 Black; 2 Asian; 5 Other,"Bristol-Myers Squibb Company paid over $515 million to the U.S. government to resolve fraudulent marketing and pricing schemes.  This settlement included 7 qui tam actions. The FDA mandated that the package for Abilify carry a ""black box"" warning for use with dementia-related psychosis. BMS knowingly promoted the same and use of Abilify for pediatric use and to treat demntia-related psychosis.  https://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html","Low risk - Computer-generated randomization. However, it was prepared by Bristol Myers Squibb, a conflict of interest. Permuted block design. ",High risk - A voice response system called a medication bottle number for each pt. ,"High risk - No report of placebo and aripiprazole forms, colors, or tastes.  ",,"High risk - PedsQL and CGSQ were stated to have had significant improvement in scores. However, the baseline scores, end point scores, or percentages were not recorded. CGI-S scores not reported. ","High risk - PedsQL, CGSQ, or CGI-S quantitative values not reported. Only improvements reported. ",
Aripiprazole and Risperidone,Yes,Yes,"Ghanizadeh, Ahmed",,No conflicts of interest. ,"June 26, 2013",Child Psychiatry and Human Development,Randomized Double-blind Placebo Controlled ; head to head comparison,2 months,59,48 M: 11 F,"4-18, Mean: 9.5 years",Aripiprazole mean: 5.5 mg/d; Risperidone mean: 1.12 mg/d. Max dose for aripiprazole was 15 mg/d and 3 mg/d for risperidone. ,Irritability,Irritability and agitation. Aberrant Behavior Checklist (ABC) scores,Both treatments lowered ABC scores with decreased irritability and agitation. ,,N/A,N/A,"The rate of adverse side effects and events were the same in both groups. Several patients withdrew for severe adverse events. Most common AEs in both treatments were increased appetite, drooling, and drowsiness. ","In the aripiprazole group, 1 participant discontinued due to hospitalization for symptoms, one dropped out due to exacerbation of epilepsy, and one dropped for severe sedation. In the risperidone group, one withdrew from lack of efficacy, one declined to return, and the other one withdrew because of agitation and crying. ",n=3 (aripiprazole); n=3 (risperidone),"""No stratification considering factors, such as age, gender, diagnoses was conducted."" ",The dosage was flexible based on efficacy in the individual subjects. Aripiprazole and risperidone are the only FDA approved medications for treating maladaptive behaviors in autism. ,,,,,,,
Aripiprazole and risperidone,Yes,Yes,"DeVane, C.",10.1002/phar.2271,No conflicts of interest. ,June 2019,Pharmacotherapy,randomized double-blind parallel-group,10 weeks (with optional 12-week extension phase),61,48 M: 13 F,6-17 y (m: 8.3-8.5),aripiprazole: 2-15 mg/d; risperidone: 0.5-3.0 mg/d,severity. irritability,ABC irritability; CGI,"psychiatric measures: All patients significantly improved on the ABC-irritability. Improvement was greater in the risperidone group. Significant improvement on CGI-S scores for both groups. 78% of patients were rated as very much or much improved on the CGI-I at 10 weeks, and all patients were rated as very much or much improved at the end of the extension phase. ",Metabolic/physical measures,"blood samples for: biochemistry profiles, lipid concentrations, hematologic indices, prolactin, and DNA profiling (genetic polymorphisms); SAS, AIMS, BARS","metabolic & physical measures: No treatment differences in blood chemistry, except prolactin. Prolactin levels increased in the risperidone group, decreased in the aripiprazole group. Weight gain was higher in the risperidone group initially, but the difference became insignificant through the extension phase.","aripiprazole: sedation, enuresis, weight gain, somnolence, difficulty sleeping; risperidone: increased appetite, drooling, weight gain ",No serious AEs,n=10 ,38 white; 19 black; 2 mixed (white/black); 1 mixed (white/Native American); 1 Asian,Biomarkers in Autism of Aripiprazole and Risperdione Treatment (BAART),unclear risk - randomization method not noted,low risk - Drugs were formulated in identical capsules and instructions were the same. ,low risk - All research personnel were blinded to treatment and dose. ,"low risk - Physicians, participants, and families were blinded to treatment allocation and dose. ",,,
Atomoxetine,No,No,"Harfterkamp, Myriam ",,No conflicts of interest reported. ,"July 1, 2012",Child and Adolescent Psychiatry,Randomized Double-blind Placebo Controlled  ,8 weeks ,97,,6-17 years ,1.2 mg/dk/d,Attention and hyperactivity.,Attention and hyperactivity. ADHD Rating Scale (ADHD-RS),The scores improved significantly. ,Attention and hyperactivity., Clinical Global Impression of ADHD-score and Conners Teacher Rating Scale-Revised: Short Form score (CTRS-R:S),"The hyperactivity subscore imrpoved significantly, but not the other CTRS-R:S scores. There were not comparable improvements on the CGI-I scores. ","Side effects included nausea, decreased appetite, fatigue, and early morning awakening. Reported in 81.3% atomoxetine patients and 65.3% placebo patients. ",No serious adverse effects and well tolerated. ,,,"Could only access the abstract, will add the last bits of information when accessed. ",,,,,,,
Atomoxetine,No,No,"Harfterkamp, Myriam",,,"May 28, 2012",Journal of the American Academy of Child and Adolescent Psychiatry ,Randomized Double-blind Placebo Controlled ,8 weeks,97,,6-17 y,1.2 mg/kg/d,ADHD symptoms,ADHD Rating scale ,ADHD-RS scores improved in the atomoxetine tx group (40.7 to 31.6) compared to placebo.,Hyperactivity ,CGI of ADHD improvement and CTRS-R:S scores,"CTRS-R:S hyperactivity subscore improved w/ atomoxetine, no other subscores. No significant improvement on CGI-I. ","Well tolerated. Nausea, decrease in appetite, fatigue, and early morning awakening. ",No serious AEs,,,Trial for patients with ADHD and ASD (comorbid). https://www.jaacap.org/article/S0890-8567(12)00307-3/fulltext,,,,,,,
Atomoxetine,No,No,"Handen, Benjamin",,,"September 2, 2015",Journal of the American Academy of Child and Adolescent Psychiatry ,"Randomized, Double-blind, 2x2 trial of ATX and Parent Training, Placebo Controlled ",10 weeks,128,,5-14 y,max: 1.8 mg/kg/d,ADHD symptoms,parent-rated DSM ADHD symptoms on the SNAP scale and HSQ,"On the SNAP, Atomoxetine with and w/o parent training, and placebo w/ parent training, were superior to placebo. Atomoxetine tx groups had superior scores for non compliance. ",,,,Well tolerated. Decreased appetite.,,,,,,,,,,,
Baclofen +  Risperidone,Yes,No (baclofen) yes (risperidone),"Mahdavinsasab, Seyedeh-Mahsa",,No conflicts of interest reported. ,"April 12, 2019",European Child & Adolescent Psychiatry,Randomized Double-blind Placebo Controlled  ,10 weeks,64,46 M: 18 F,3-12 y; Mean: 8 y,Baclofen: 0.6 mg Kg^-1 3x/day; Max dose of Risperidone was 1 mg/d for pts under 20kg and 2 mg/d for pts 20 kgo,Irritability,ABC-irritability,"Baclofen adjuvant risperidone treatment showed significant improvement in ABC-irritability scores, as well as all other subscales. Specifically hyperactivity (refer to secondary results).",,ABC-C: all other subscales. ,"Pts treated with Baclofen and Risperidone had a greater improvement effect on hyperactivity symptoms than placebo and risperidone. The baclofen + risperidone group, showed significantly greater improvement in all ABC subscales (irritability, lethargy, stereotypic behavior, hyperactivity, and inappropriate speech)",Common side effects included increased appetite (21%) and vomiting (17%),No serious adverse events in either tx group. ,n=6 ,Not reported. ,"""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we",,,,,,,
Baclofen +  Risperidone,Yes,No (baclofen) yes (risperidone),"Mahdavinsasab, Seyedeh-Mahsa",10.1007/s00787-019-01333-5,No conflicts of interest reported. ,April 2019,European Child & Adolescent Psychiatry,Randomized Double-blind Placebo Controlled  ,10 weeks,64,46 M: 18 F,3-12 y; Mean: 8 y,Baclofen: 0.6mg Kg^-1 3x/day; Max dose of Risperidone was 1mg/day for pts under 20kg and 2mg/day for pts 20kg and over,Irritability,ABC-irritability,"Baclofen adjuvant risperidone treatment showed significant improvement in ABC-irritability scores, ","Lethargy/social withdrawal, stereotypy, and hyperactivity/noncompliance",ABC-C: all other subscales. ,Baclofen and risperidone treatment showed improvement on all subscales of the ABC (highest on hyperactivity),Increased appetite,No serious AEs,n=6 ,Not reported. ,"""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we",,,,,,,
Balovaptan,Yes,No,"Hollander, E",10.1001/jamapsychiatry.2022.1717,Hoffman-La Roche Ltd.,July 2022,JAMA Psychiatry,RCT,24 weeks,167,139 M: 28 F,5-17 y; mean: 12 y,4 mg or 10 mg,Social communication,Vineland-II 2DC,No significant improvement in any outcome measures.,Social communication,Vineland-II ABC; PedsQL; ABC lethargy/social withdrawal; CGI-I; CGI-S,No significant improvement in any secondary outcome measures.,Well tolerated,No serious AEs linked to balovaptan.,n=32,133 white; 10 Asian; 8 black/African American; 1 Pacific Islander; 13 multiple; 2 unknown,,Low risk - Randomized using interactive responce system.,Unclear risk - Tablets or liquid taken once per day. Matching for taste and color was not reported.,Low risk - Assessors were blinded.,Low risk - Clinicians and participants were blinded.,"Unclear risk - Most outcome data reported, but not ABC scores.",Low risk ,
Bumetanide,Yes,No,"Lemonnier, E",10.1038/tp.2012.124,No conflicts of interest. ,"December 11, 2012",Translational Psychiatry ,Randomized Double-blind Placebo Controlled  ,"4 months (3 month treatment, 1 month washout)",60,89% M; 11% F,3-11 y,0.5 mg BID,ASD Severity,CARS scores,"The group treated with Bumetanide had a significately lower score on the CARS test at endpoint, when removing the most severe cases of ASD in this group. This group shifted from extreme severity to mild/moderate severity. ",ASD severity,CGI and ADOS scores,"ADOS and CGI scores decreased moderately for the bumetanide treatment group, however it this treatment was less efficient with patients severely affected by autism. ",Limited side effects. Hypokalemia,Generally safe. ,n=6 ,not reported,,Unclear risk - randomization method not reported,"Low risk - Bumetanide and placebo were matched for smell, taste, and viscosity. ",Low risk - Independent evaluators were blinded. ,"Low risk - Participants and clinicians were blinded to the treatment allocation, the labeling of the medication was hidden.","Unclear risk - Scores from the outcome measures were reported. However, incidences of side effects were not.",Low risk - All measurement data was reported. ,
Bumetanide,Yes,No,"Dai, Yuan",https://doi.org/10.1016/j.scib.2021.01.008,No conflicts of interest,Dec-20,Science Bulletin,RCT,3 months,119,19 F: 100 M,3-6 y; mean: 4.03-4.22 y,0.5 mg BID,ASD Severity,CARS,Bumetanide treatment improved CARS scores. ,ASD severity,"ADOS, SRS, and CGI-I; Exploratory: GABA and glutamate concentrations within the IC",Bumetanide treatment was better at reducing insular GABA. No significant treatment group difference in ADOS scores. The bumetanide group had more CGI-I responders.,Well tolerated. Polyuria and mild hypokalemia,"No withdrawal from adverse events, no serious adverse events. Mild hypokalemia developed in some participants but was resolved with potassium supplementation.",n=3,not reported,,Low risk - Participants randomly assigned using a block randomization scheme,"Low risk - Bumetanide and placebo were identical in appearance, smell, and taste. ",Low risk - Assessors were blinded,Low risk - All clinicians and participants were blinded. ,"Unclear risk - Results for CGI-I outcome was reported as ""responder"" versus ""non-responder"". SRS scores not reported.",,
Bumetanide,Yes,No,"Sprengers, Jan",10.1016/j.jaac.2020.07.888,"ZonMW, NOW, Aspect Neuroprofiles BC",July 2020,Journal of the American Academy of Child & Adolescent Psychiatry,Randomized Double-blind Placebo Controlled ,91 days,92,63 M: 29 F,7-15 y; m= 10.5 y,"0.03 mg/kg BID for <30kg; 1.0 mg BID for 30 kgo - participants supplemented with potassium chloride: 0.5 mmol/kg if <30kg, or 8 mmol BID if 30 kgo",Severity of social communication and social interaction symptoms,SRS-2 total score,"No significant treatment effect for SRS-2 total scores. However, there was a significant treatment-by-age effect on the SRS-2.","Severity of restricted and repetitive behaviors, and behavioral responses to sensory stimuli",RBS-R; Sensory Profile (SP-NL); ABC-irritability,Significant treatment-by-sex effect on RBS-R. No effect on the SP-NL or ABC-I scores. ,"Well tolerated with mild to moderate AEs. Most common AEs: hypokalemia, dehydration, orthostatic hypotension, and diuresis. ",One serious AE of syncope after venipuncture requiring short term clinical observation. ,"n=4 (2 placebo, 2 bumetanide)",not reported,,Low risk - sequence generation overseen by third party using restricted randomization using permuted block design,"Low risk - Allocation was masked with a medication kit number given to participant. Bumetanide and placebo were matched for taste, smell, and viscosity.  ",Low risk - Outcome assessors were blinded. ,"Low risk - All participants, parents, and clinicians were blinded. All subjects were given the same instructions (increase fluid intake & identical potassium regimens)",Low risk - All assessment scores and statistics reported. ,Low risk - Significant and insignificant results reported. ,
Buspirone + risperidone,Yes,Yes,"Ghanizadeh, Ahmed",https://doi.org/10.1016/j.pediatrneurol.2014.09.017,,October 2014,Pediatric Neurology,RCT,8 weeks,40,,,mean: 6.7 mg/d (SD 2.7),Irritability,ABC ,Irritability scores decreased in both groups. ,,,,"Well tolerated. Increased appetite, drowsiness, fatigue",No serious AEs,n=6 ,,,,,,,,,
Buspirone,No,No (baclofen) yes (risperidone),"Chugani, Diane",,No conflicts of interest. ,March 2016,The Journal of Pediatrics,Randomized Double-blind Placebo Controlled  ,24 Weeks,166,29 F: 137 M,2-6 y,Placebo; 2.5mg (n=54) po BID; 5.0mg po BID (n=55) ,Restricted and repetitive behavior,ADOS Composite Total Score (ADOS-CTS),Significant improvement with time but no difference in scores between baseline and end of trial across the 3 treatment groups. ,,"RBS, Anxiety Composite, ADOS-SA and ADOS-RRB, CYBOCS, Vineland communication domain",ADOS-SA scores showed significant improvement with time. No difference between treatment groups. ADOS-RRB scores showed significant improvement in the 2.5mg treatment group. No change in scores for the placebo and 5.0mg groups. ,Pyrexia and irritability. There was no significant difference between side effects among the three groups. ,Generally safe. ,14%,1% American Indian/Alaska Native; 1% Asian; 31% Black/African American; 2% Hawaiian; 58% White; 7% Other,"This trial supports that lower dosage of buspirone could be more beneficial than higher doses in improving social competency, and reducing restrictive and repetitive behaviors in children with ASD.",Unclear risk - Study states that patients were randomized in blocks for age groups. ,Low risk - Placebo and busprione were dissolved into orasweet at either 2.5 mg or 5 mg.,Low risk -  Assessors were blinded. ,Low risk - All clinicians and participants were blinded to treatment group. ,Low risk - All outcome data was reported. ,"Low risk - All outcome measures were reported, even insignificant findings. ",
Cannabinoid (whole-plant cannabis extract and delta 9 THC; pure CBD and delta 9 THC),,,"Aran, Adi",10.1186/s13229-021-00420-2,BOL Pharma (Aran and Castellanos),2021,Molecular Autism,Randomized Double-blind Placebo Controlled   - Crossover,"24 weeks (12 week randomized, 12 week crossover)",150,80% M: 20% F,5-21 y (m: 11.8 y; SD: 4.1 y),20-40 kg: 1 mg/kg/d CBD and 0.5 mg/kg/d THC; 40 kgo: 7.5 mg/kg/d CBD and 0.375 mg/kd/d THC,Behavioral problems,Home Situation Questionnaire-ASD (HSQ-ASD); CGI improvement (CGI-I) with disruptive behavior anchor points,CGI-I was either much or very much improved in 49% of participants receiving whole-plant canninoids. Pure cannibinoid and placebo groups did not have signifcant effects on the CGI-I. HSQ-ASD did not have differences in any groups. ,"Social behavior, parent stress",SRS-2; Autism Parenting Stress Index (APSI),APSI did not have a treatment effect for cannabinoid compared to placebo groups. The median SRS total score improved more in cannibinoid group than placebo (p=0.009). ,Well tolerated. AEs: somnolence and decreased appetite,No serious AEs,n=18 ,not reported,,low risk - Randomization generated by external consulting firm (BioStats) and SAS statistical software for blocks. ,"low risk - Pure cannabinoid and whole-plant extract mixed with placebo to ensure concealment. All allocations packed in similar bottles with similar taste, color, and smell. Placebo solution was prepared with olive oil, oleoresin oregano, raspberry o.s, and paprika color to mimick the cannabinoid. ",low risk - The principal investigator and other team members were blinded throughout entire study. Code key was kept by the external consulting company (BioStats). ,"Low risk - All personnel, including clinicians and participants, were blinded through entire study. ",low risk - All outcomes reported in supplemental data file. ,Low risk - Insignificant results reported and noted. All outcomes reported in supplemental data file.,"Low risk of biases (as according to Cochrane) on all aspects of trial. Supplemental figures with detailed randomization, assessment, scores, adverse events, etc."
Celecoxib + risperidone,,,"Asadabadi, Mahtab",https://doi.org/10.1007/s00213-012-2796-8,No conflicts of interest,July 2012,Psychopharmacology,RCT,10 week,40,25 M: 15 F,5-11 y (m: 7.5 y),risperidone max: 3 mg/d; celecoxib max: 300 mg/d,Irritability,ABC-C irritability,Combination of risperidone and celecoxib showed greater improvement in irritability.,"Social communication, stereotypic behavior, hyperactivity/noncompliance",ABC-C: all other subscales. ,"Combination of risperidone and celecoxib showed greater improvement in lethargy/social withdrawal, and stereotypic behavior. No significant improvement in hyperactivity/noncompliance or inappropriate speech.","Side effects were the same for both risperidone + placebo, and risperidone + celecoxib. Increased appetite, sedation, nausea, insomnia",Generally safe,none,Not reported. ,,low risk - Computer generated randomization.,low risk - Allocation was sealed in opaque envelopes until data analysis.,low risk - Assessors were blinded.,"low risk - Patients, clinicians, and parents were blinded.",Low risk - All data reported ,"Low risk - All data reported, including insignificant results. ",Low risk
Citalopram,Yes (peppermint),Yes,"King, Bryan",,"National Institutes of Health, BioMarin, Neuropharm, Forest Labratories, Nastech, and Seaside Therapeutics, Bristol-Meyers Squibb, Abbott Labs, UCB Pharma, Shire, Pfizer, Johnson & Johnson",June 2009,Arch Gen Psychiatry,Randomized Double-blind Placebo Controlled  ,12 weeks,149,128 M: 21 F,"5-17, Mean: 9.4 years",10 mg/5mL; mean: 6.5 mg/d,,"Clinical Global Impressions, Improvement subscale scores",No significant differences in improvement of scores between placebo and citalopram treatment groups. ,Repetitive/obsessive behaviors., Children's Yale-Brown Obsessive Compulsive Scale scores,No difference in score reduction between the placebo and citalopram treatment groups. ,"16 subjects withdrew due to adverse events. AEs were more common in the citalopram treated group (97.3% reported at least 1). Most common side effects were increased energy, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, and dry skin. ","Two subjects treated with citalopram had seizures. One had a prior condition, the other had a ""prolonged seizure with loss of consciousness, and required emergency hospitalization"".",n=26 (13 in both groups),108 White; 17 Black; 1 Native Hawaiian; 2 American Indian/Alaska Native; 10 Other,Lack of efficacy of Citalopram in treatment of bx in ASD.,,,,,,,
D-cycloserine,,,"Urbano, Maria",10.1176/appi.neuropsych.13070155,,,,,,,,,,,,,,,,,,,,,,,,,,,
Digestive enzyme supplementation,,,"Munasinghe, Sujeeva",,"The authors did not state conflicts or interest, nor no conflicts of interest.",March 2010,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled  - Crossover,6 months,43,"21 M (seq 1), 22 M (seq 2)",3-8 y,2 capsules with each meal (1 capsule recommended to be given with snacks containing gluten or casein),Behavior and communication skills,Global Behaviour Rating Scale (GBRS); Language Development Survery (LDS); Therapist Rating Scale (therapist engagement),"No effect of enzyme treatment on LDS vocabulary or sentence complexity scores, parent behaviour, or therapist engagement. ","GI symptoms, night-time sleeping quality, and food variety","Additional Rating Scale: GI symptoms (quality of stools, abdominal pain, presence of diarrhea, constipation), food variety score (range of foods eaten), sleep quality score",No improvement in GI symptoms or sleep quality. Food variety score increased for the enzyme treatment (p=0.02; confidence interval: 0.03-0.37),,,n-16 (10 enzyme),not reported,,low risk - computer based randomization,"low risk - Capsules were identical in size and outer cover, ""as close as possible in taste and smell"". Pharmacist provided capsules and bottles were dispensed by blinded researchers.",low risk - Clinical assessors were blinded to allocation. ,low risk - Participants and families blinded to sequence allocation. ,,,
Divalproex sodium,Yes (cherry),Yes,Hollander,,,2006,,Randomized Double-blind Placebo Controlled ,,13,not noted,,"500-1500 mg/d (m: 822.92 mg/d, SD: 326.1)",,C-YBOCS,,,,,,,,,,,,,,,,
Divalproex Sodium (Valproate),Yes (cherry),Yes,"Hollander, Eric",10.1038/npp.2009.202,"Consultation fees from Abbott, neuropharm, Nastech, BMS, and Forest. Hollander has intellectual property related to oxytocin and memantine. InteGragen, and USB Pharma. ","December 9, 2009",Neuropsychopharmacology,Randomized Double-blind Placebo Controlled  ,12 weeks,27,23 M: 4 F,5-15 y; Mean: 9.5 y,Titrated up according to body weight. Minimum level was 50ug/ml. 125mg po QH5-250mg po BID for <40kg. 250 mg po QHS-500mg po BID for >40kg,Irritability,"CGI-I for irritability and ABC-Community, Irritability subscale","CGI Scores indicate that ""subjects receiving treatment with divalproex sodium are over 16 times more likely to respond to treatment than... placebo"".  Significant weeks x condition interaction on the ABC-I. The effects seem stronger in the tx groups, as the ABC-I scores dropped significantly more than the placebo group. ",Irritability.,"OAS-M Irritability subscale and the CYBOCS. Exploratory measures: Vineland adaptive behavior scale, YMRS, and EEG","No remarkable results for secondary or exploratory measures. No significant difference in treatment groups for OAS-M,  CYBOCS, Vineland scores, or CGI-I scores. ","Insomnia, weight gain, headache, rash, polyuria, and agitation. Side effects ranging from mild to moderate intensity. ",One child with significant weight gain. Very good safety profile. No serious Aes. ,"n=3 (2 withdrew for side effects, 1 for nonefficacy)",8 White non-hispanic; 6 Hispanic; 6 Black; 3 Asian; 2 Other; 2 More than one race,,Unclear risk - method of sequence generation not described,Unclear risk - method of allocation not reported,Low risk (blinding of personnel) - Efficacy measured by an independent evaluator. ,Low risk - All clinicians involved in measuring safety and efficacy were blinded. ,Low risk ,Low risk,
Donepezil,No,Yes,"Chez, MG",,,2003,Journal of Pediatric Neurology,Randomized Double-blind Placebo Controlled ,6 weeks,43,,Mean: 6.8 y,,Speech,,Improvements in expressive and repetitive speech,,,Decrease in overall autistic bx in tx group,Diarrhea and stomach cramps ,,,,,,,,,,,
Donepezil,No,Yes,"Handen, BL",,,2011,Journal of Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled ,10 weeks,34,,8-17 y,5-10 mg/d,,,No significant improvements in the donepezil tx group compared to the placebo group.,,,,,No serious adverse events. ,,,,,,,,,,
Fenfluramine,,,"Leventhal, BL",10.1176/jnp.5.3.307,,1993,The Journal of Neuropsychiatry and Clinical Neurosciences,double-blind placebo-controlled crossover trial,62 weeks,15,,,60 mg/d,Neurochemical effects and behavior,Ritvo-Freeman Real Life Rating Scale; neurochemical plasma levels ,No significant improvement in behavior. Changes in catecholamine regulation might be related to fenfluramine in plasma. Increase in DOPAC. Decreases in whole-blood 5-HT during trial. Decreases in plasma NE until as long as 8 weeks after trial.  ,"Hyperactivity, motor abnormalities, cognition, social, and affectual responses",parent and teacher ratings of hyperactivity,"Hyperserotonemic and normoserotonemic participants response did not differ. Significant improvement in motor abnormalities and parent reported hyperactivity, but no p values were reported. No treatment related effect on abnormal social and affectual responses, or cognition.",Weight loss,,,,https://europepmc.org/article/med/8369641,Unclear adequacy and risk,Unclear adequacy and risk,"Unclear risk - Used the term ""double blinding"" in reference to all blinding. ",Low risk ,Unclear risk ,Unclear risk ,
Fenfluramine,,,"Barthelemy, C.",,,June 1989,Journal of Autism & Developmental Disorders,,3 months,13,,,1.5 mg/kg/d ,Urinary dopamine metabolities ,"Responsiveness to fenfluramine and associated urinary levels of serotonin, dopamine (DA), and DA metabolites: HVA and Dihydroxyphenylacetic acid (DOPAC)",Both placebo and fenfluramine treatment groups showed a significant decrease of of 5-HT in urine. Fenfluramine increased HVA levels (major metabolite of dopamine) in responders. The clinical response to fenfluramine treatment could be related to dopaminergic action of this medication and urinary levels of dopamine metabolites could indicate this responsiveness.,"Motor activity, anxiety, mood disturbances, and distractability (responsiveness).",,6 children were classified as responders to fenfluramine.,,,n=0,,,Unclear adequacy and risk ,Unclear adequacy and risk,Unclear risk - Did not report if outcome assessors were blinded. ,Low risk - Reported blinding of participants and treating physicians. ,Low risk - No loss to follow up. ,Unclear risk - Trial did report negative outcomes. Trial did not report all outcome measures and was not preregistered. ,
Fluoxetine,Yes,Yes (cherry),"Hollander, Eric",,Two authors consulted for Neuropharm. Dr. Hollander has consulted for Abbott and Forest Dr. Anagnostou has consulted to Novartis and Proximagen. ,March 2012,The American Journal of Psychiatry  ,Randomized Double-blind Placebo Controlled ,12 weeks,37,26 M: 11 F,"18-60 y, Mean: 34 y",20-80 mg/d; mean: 64.76 mg/d,Repetitive behaviors.,Yale Brown Obessive Compulsive Scale (YBOCS); CGI improvement for repetitive behaviors,Fluoxetine resulted in 'significantly greater improvements in repetitive behaviors'. ,"Global severity, irritability, depression",ABC irritability; Hamilton Depression Rating Scale (HAM-D); CGI improvement of overall symptoms,ABC irritability score changes were not significant. CGI improvement on global measures was more significant in the fluoxetine group. ,"Well tolerated. Few side effects were observed. Side effects included, bad/vivid dreams, mild insomnia, dry mouth, and headaches. ","Side effects were mild to moderate. Suicidal ideation was uncommon in both groups, and no suicide attempts were reported.  No serious adverse events. ",n=4 ,73% White; 11% Black; 3% Asian; 5% Hispanic; 8% Other ,,Unclear risk - randomization method not reported,"Low risk - Placebo and fluoxetine were identical, both groups were titrated up with the fluoxetine/placebo capsules. ",Low risk - All outcome assessors were blinded,Low risk - All clinicians and participants were blinded.,Unclear risk - Scores for all measures except for HAM-D were reported. ,"Unclear risk - Baseline and endpoint scores for ABC-irritability were not reported, p value reported (p=0.15), which was insignificant. Scores that were favorable for fluoxetine were reported. HAM-D scores were not reported, so it is unknown whether there was no difference or if there was an increase in either group. ",
Fluoxetine,Yes,Yes (cherry),"Chantiluke, Kaylita",,"K.R. received funding from Lilly for another project and speaker's honoraria from Lilly, Shire, Novartis and Medice. M.B. is a consultant for P1 Vital, Oxford, UK,. ","January 22, 2014",Oxford University Press,Randomized Double-blind Placebo Controlled  , Pts scanned twice after 5 hours after administration. Each scan was 3-4 weeks apart. ~8 weeks,54,100% M,10-17 years ,"8-15 mg. Titrated to age and weight. 10-13 yrs and <30kg: 8mg, >30kg: 10mg; 14-17 yrs and <30kg: 10mg, >30kg: 15mg. ",,fMRI during a reward reversal task -- mPFC (reward) activity in ASD,"In fluoxetine tx ASD pts, mPFC activation was up-regulated and normalized, and decreased insula activation. Fluoxetine has ""disorder-dissociative, inverse modulation effects on a key region of reward reversal"".",,fMRI during a reward reversal task -- medial prefrontal cortex activilty in ADHD,Fluoxetine tx resulted in a reduction of activation in mPFC in pts with ADHD. ,Well tolerated. Side effects not reported. ,No serious Aes. ,"n=10, due to dislike of MRI scanner. ",Not reported. ,"There is an inverse effect on mPFC activation between the 2 disorders, which could point to differences in baseline levels of 5-HT and seratonergic regions. ",,,,,,,
Fluoxetine,Yes,Yes (cherry),"Reddihough, Dinah S. ",,"NHMRC, Royal Children's Hospital Foundation, Shire, Medice, Newron Pharma, Health Tracker Ltd. ","October 22, 2019 ",The Journal of the American Medical Association,Randomized Double-blind Placebo Controlled  - Multisite,16 weeks ,146,85% males; 15% females ,Mean: 11.2 years,"4 or 8 mg/d for the first week, titrated to max dose of 20 or 30 mg/d",Obsessive-compulsive/repetitive behaviors,. Total score on CYBOCS-PDD,Treatment with fluoxetine resulted in significantly lower scores for obsessive-compulsive behaviors at the end of the trial. ,Anxiety and reactivity.,"RBS-R, Spence Children's Anxiety Scale, ABC-Community, CGI-Global Improvement and Efficacy Index, Disruptiveness Assessment, Adverse events ",No significant differences in the fluoxetine and placebo groups. ,"Mood disturbance (irritability), nausea, diarrhea, and sleep disorders. ",2 participants in the placebo group experienced suicidality. No serious Aes in the fluoxetine group. ,n=31 fluoxetine; n=21 placebo,not reported ,"""Interpretation is limited by the high drop out rate, null findings of prespecified analyses that accounted for potentially cofounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference.""",,,,,,,
Fluoxetine,Yes,Yes (cherry),"Hollander, Eric",10.1038/sj.npp.1300627,No commercial affiliations,2005,Neuropsychopharmacology,RPCT - Crossover,16 weeks ,45,,5-16 y,mean final dose: 9.9 mg/d (SD: 4.5 mg),repetitve behaviors and global improvement,CY-BOCS and CGI-AD composite scores,Combined CY-BOCS and CGI-AD scores lead to a trend in a reduction of ASD severity.,global improvement,CGIS-AS,No improvement in CGIS-AS. ,No difference in AE severity or incidence in fluoxetine and placebo groups. Dose reduced due to agitation in 6 fluoxetine treatment participants. ,Generally safe,,,https://www.nature.com/articles/1300627,Unclear risk - method of sequence generation not described,unclear - Allocation concealment method not reported.,Low risk -  Assessors were blinded. ,Low risk - Clinicians and participants were blinded.,High risk - Participants excluded for lack of efficacy and noncompliance with therapy.,"Unclear risk - The trial was not registered before commencement, but negative outcomes were reported.",
Fluvoxamine,No,No,"McDougle, Christopher J. ",,"Abraham Ribicoff Research Facilities, connecticut Mental Health Center, Yale University ",November 1996 ,Arch Gen Psychiatry ,Randomized Double-blind Placebo Controlled  ,12 weeks,30,,Adults (18+),,"Repetitive behaviors, and aggression.","Repetitive thoughts and behaviors, and aggression. Clinical Global Impressions- Improvement (CGI-I)","Fluvoxamine is more effective than placebo in reducing repetitive thoughts and behaviors, maladaptive behavior, and aggression. Improved some aspects of social relatedness. ",,None,N/A,Well tolerated. Side effects of mild sedation and nausea. ,"Generally safe. No dyskinesias, adverse cardio events, or seizures occurred. ",,,,,,,,,,
Fluvoxamine,No,No,"Sugie, Yoko",10.1007/s10803-005-3305-2,,June 2005,Journal of Autism & Developmental Disorders,double-blind Randomized Double-blind Placebo Controlled  - crossover,12 weeks ,18,15 M: 4 F,3-8.4 y (m: 5.3 y),"1 mg/kg/d for 2 weeks, 2 mg/kg/d for 3 weeks, 3 mg/kg/d for 6 weeks, 1.5 mg/kg/d for 2 weeks",Molecular genetic analysis,efficacy of fluvoxamine and serotonin transporter gene (5-HTTLPR) polymorphism,5-HTTLPR long (l) or short (s) alleles might influence fluvoxamine behavior response. ,Core features of autism and adverse effects,Behavior Assessment Scale (BAS); CGI for different genotypes; adverse effects measured by blood biochemistry,"For the BAS, 10 out of 18 patients ""responded"" to fluvoxamine treatment. ""Clinical global effectiveness was noted significantly more in the l allele than in the s allele.""",No significant differences in instances of AEs between groups noted in blood tests. Self reported and clinician reported AEs were not assessed.,No significant adverse events noted.,n=1,,,low risk (adequate) - computer generated randomization,low risk ,Unclear risk - Outcome assessors blinding status not clarified. ,"Unclear risk - Used term ""double blinding"" which is subjective and there is potential for bias. ",Low risk - Reported not using an intention-to-treat analysis. ,High Risk - Only reported effectiveness for genetic subgroups. ,
Fluvoxamine,No,No,,,,,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled - Crossover  ,26 weeks,20,15 M: 4 F,3-8 y; mean: 5 y and 4 mo,,Genetic polymorphism in patients w/ autistic disorders,"Three genotypes (1/1, 1/s, s/s) based on Polymerase chain rxn (PCR) products on a stained gel. ",,,,,,,,,,Low risk - Computer generated ,Low risk - Placebo and Fluvoxamine were identical powders,,,,,
Folinic acid (high-dose),,,"Frye, RE",,"EVQ and JMS are inventors in a patent for detecting of the autoantibodies described in this study issued to the Research Foundation of the SUNY. REF and EVQ are members of the advisory board to Illiad Neurosciences, Inc.","October 18, 2016",Molecular Psychiatry,Randomized Double-blind Placebo Controlled ,12 weeks,48,82% M,Mean: 7 y,"5, 10, or 25mg; Max: 50mg/day",Verbal communication.,"Verbal Communication. CELF-preschool-2, CELF-4, PLS-5",Verbal communication improvement was significantly greater in the folinic acid tx group. ,,"OACIS, VABS, ABC, SRS, BASC, AIM, and ASQ","The daily living skills on the VABS and internalizing problems on the BASC significantly improved. Improvement in irritability, lethargy, stereotyped bx, hyperactivity, inappropriate speech, and total score on ABC. ASQ stereotypic bx and total score improvement.","Common side effects: excitement/agitation, insomnia, increased motor activity. No differences between side effects in the folinic acid and placebo groups. ",No serious AEs in the folinic acid group. One child in the placebo group was unblinded and removed due to serious AE. ,n=5,Not reported ,This study suggests that FRAAs predict response to high-dose folinic acid tx. ,,,,,,,
Folinic acid + Risperidone,Yes (risperidone),Yes (risperidone),"Batebi, Neda",,No conflicts of interest.,"October 7, 2020",Child Psychiatry and Human Development,Randomized Double-blind Placebo Controlled ,10 weeks,55,35 M: 20 F,Mean: 13.4 y (SD: 2),"Risperidone- 1-2 mg/d (Flexible based on weight). Under 20 kg max: 1 mg/d, pts 20 kgo max: 2 mg/d, + Folinic acid: 2 mg/kg/d, up to 50 mg/d; or + placebo",Social behaviors and inappropriate speech. ,Inappropriate speech subscale of ABC-C,Inappropriate speech subscale score showed more improvement in the folinic acid group compared to placebo (both w/ risperidone). Significant time x treatment effect on the inappropriate speech subscale.,"Lethargy/social withdrawal, stereotypy, and hyperactivity/noncompliance",ABC-C: all other subscales. ,,Well tolerated. Common side effects: increased appetite and diarrhea. ,No serious adverse events in either tx group. ,n=11,Not reported.,"Both the folinic acid and placebo groups showed improvements in all ABC-C subscales over the course of the treatment, confirming that risperidone is beneficial in relieving ASD symptoms. ",Low risk - Computer generated randomization with microsoft excel,Low risk - Allocations were kept in sealed and confidential envelopes.,"Low risk - ""Placebo capsules were completely indistinguishable to folinic acid, regarding shape, size, color and taste"". ","Low risk - Participants, parents, and researchers were blinded to allocation. ","Low risk - All measurement outcome data was reported in a table, and graphs. ",Low risk - All measurement outcome data was reported including improvements in the placebo group. ,
Galantamine,Yes,No,"Niederhofer, H",,,2002,BMJ,Randomized Double-blind Placebo Controlled ,,20,,Mean: 7.4 y (SD: 3.2),,,ABC,"Significant improvement compared to placebo on the ABC irritability, eye contact, hyperactivity, and inappropriate speech. ",,,,Well tolerated with minimal side effects. ,Generally safe. ,,,,,,,,,,
Galantamine,Yes,No,"Ghaleiha, A",,,2014,Journal of Psychopharmacology,Randomized Double-blind Placebo Controlled ,10 weeks,40,,4-12 y,up to 24 mg/d,Lethargy/social withdrawal.,,Significant improvements in lethargy/social withdrawal. ,Irritability,,Significant improvements in irritability. ,Side effects were similar in the placebo and tx group. Including verbal/bx regression and headaches. ,,,,,,,,,,,
Ginko biloba + Risperidone,,,"Hasanzadeh, Elmira",,No conflicts of interest. ,"March 6, 2012",Child Psychiatry & Human Development,Randomized Double-blind Placebo Controlled  - Pilot,10 weeks,47,39 M: 8 F,4-12 y; mean: 6.4 y (SD: 2.2),"Risperidone: 1-3 mg/d + Gingko: 80 mg/d (pts under 30 kg), 120 mg/d (pts 30 kg); or + placebo",Core symptoms of ASD.,ABC-C ,No subscales showed differences between treatment groups. Ginko adjuvant risperidone did affect treatment outcomes.,Side effects,Side effect check list,No difference in frequency or types of side effects between groups. ,Well tolerated.,Generally safe,n=0,Not reported. No significant demographical differences between tx groups. ,,,,,,,,
Guanfacine (ER),No,No,"Scahill, Lawrence",10.1176/appi.ajp.2015.15010055,"Shire Pharmaceuticals provided guanfacine and placebo. Bracket, Coronado, MedAdvante, Neuren, Roche, and Shire. Seaside Therapeutics. ","August 28, 2015",The American Journal of Psychiatry  ,RCT - multisite,16 Weeks,62,9 F: 53 M,5-14 y; Mean: 8.5 y,1-4 mg/d; mean: 3 mg/d,Hyperactivity,. Aberrant Behavior Checklist- Hyperactivity Subscale (ABC-H),"""Guanfacine was superior to placebo on the parent-rated Aberrant Behavior Checklist-hyperactivity subscale"" A 43.6% decline in the scores of the guanfacine group, compared to a 13.6% decrease in the placebo group. ",,Clinical Global Impressions-Improvement (CGI Scores) and the ADHD Rating Scale scores,"Guanfacine showed more improvement than placebo  in the ADHD Rating Scale scores, as well as, a higher rate of positive response on the CGI scores. There was a 50% positive response in the treated group compared to 9.4% in the placebo. ","Lowered blood pressure was the most common side effect. Nine subjects lowered dosages, because of effects such as, drowsiness, irritability, sleep reduction, or emotion dysregulation (""emotionally fragile or tearful and cranky""). ",Two participants dropped out due to Aes. One child had a serious AE and discountinued guanfacine. He became physically and verbally aggressive towards his mother and hospital personnel.,n=8;  All dropouts due to lack of efficacy.,30 White; 11 Black; Asian; 2 Pacific Islander; 4 Mixed,,"Unclear risk - method of sequence generation not described; ""eligible subjects were randomly assigned within site without stratification in a 1:1 ratio...""",Low risk - Permuted blocks used for allocation concealment. ,,,,,
Haloperidol,Yes,,"Campbell, M",,,1982,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled ,12 weeks ,42,,2.6-7.8 y,,Stereotypy and social withdrawal.,Stereotypy and social withdrawal subscales of CPRS.,Haloperidol was superior to placebo on sterotypy and social withdrawal scores.,,,,Sedation and acute dystonic reactions.,Acute dystonic reactions in 2 pts.,,,"There was more of a ""positive impact on learning when haloperidol treatment was combined with language training"".",,,,,,,
Haloperidol,Yes,,Anderson,,,1989,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled ,14 weeks,45,,2.3-7.9 y,,Withdrawal and stereotypy,CPRS,Haloperidol superior to placebo on all subscales of CPRS. No significant treatment benefit in irritability symptoms. ,,,,"Sedation, increased irritability","Shown to have long term safety and efficacy, though there is risk for dyskinesia. ",,,,,,,,,,
Intranasal Oxytocin,,,"Anagnostou, Evdokia",,"Proximagen, Neuropharm, Seaside Therapeutics, and Novartis",2012,Anagnostou et al. Molecular Autism,RPCT- Pilot ,6 weeks,19,16 M: 3 F,Mean: 33 y,24 IU BID,,Social function/cognition (Diagnositic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale-Revised),No significant changes in primary outcome measures. ,"Social, obsessive behaviors, and emotional states. ","Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and Yale Brown Obsessive Compulsive Scale - compulsion subscale, and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales)","Improvements in the measurements of social cognition, Reading-the-Mind-in-the-Eyes Test and quality of life. ",Well tolerated. ,No serious adverse effects. ,n=3,73.7% White; 5.2% Black; 5.2% Hispanic; 10.5% Asian; 5.2% Other,IN-OXT has a very short half-life in the blood. ,,,,,,,
Intranasal Oxytocin,,,"Parker, Karen",,No conflicts of interest. ,"July 25, 2017",PNAS,RPCT - Parallel design,4 weeks,32,27 M: 5 F,"6-12 years, Mean: 8/9 years",24 IU BID,Social behaviors. ,Improvement in social abilities measured by the Social Responsiveness Scale (SRS).,"Oxytocin significantly enhanced social abilities in participants. ""individuals with the lowest pretreatment OXT concentrations showed the greatest social improvement""",,Treatment efficacy in nonsocial symptom domains and OXT safety/tolerability. ,,Well tolerated with minimal side effects. Increase in blood pressure in OXT treated participants. ,,n=2 ,14 white; 9 asian; 9 other,,,,,,,,
Lamotrigine,No,Yes,"Belsito, Karin M.",,Glaxco-Wellcome,2001,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled  - Parallel,18 weeks ,28,27 M:1 F,3-11 y; mean: 5.8 y,mean: 5.0 mg/kg/d,,"ABC, Autism Bx Checklist, Vineland Bx Scales, PL-ADOS, or CARS",No significant results in diference between tx groups.,,,,Insomnia and hyperactivity. Well tolerated with limited side effects.,"No rashes. 6 pts dropped out due to adverse events (insomnia, increased stereotypies and aggression)",n=7,89.5% white Lamotrigine group; 66.7% white in placebo group,,,,,,,,
L-Carnosine,,,"Mehrazad-Saber, Zahra",,No conflicts of interest.,"January 30, 2018",Basic & Clinical Pharmacology & Toxicology,Randomized Double-blind Placebo Controlled  ,2 months,43,31 M: 12 F,,500 mg/d,Sleep habits and autism severity.,Children's Sleep Habits Questionnaires and Gilliam Autism Rating Scale 2,"Did not change autism severity. Signficantly reduced sleep duration, parasomnias, and total sleep disorders score by 7.59%.",,,,,,n=7,,,,,,,,,
Levetiracetam,,,Wasserman. Stacy,10.1097/01.yic.0000224787.13782.0f,,November 2006,International Clinical Psychopharmacology,Randomized Double-blind Placebo Controlled ,10 weeks ,20,17 M: 3 F,5-17 y ,20-30 mg/kg/d,Global improvement,CGI-I,No significant improvement.,"Aggression, affective instability, repetitive behaviors, impulsivity, and hyperactivity",ABC parent and teacher ratings; CY-BOCS; Conners' Rating Scale-Revised: Long version for parent and teacher,No significant change in any secondary measures.,,,,,,,,,,,,
Levocarnitine,,,"Geier, David",PMID: 21629200,No conflicts of interest,"June 1, 2011",Medical Science Monitor,Randomized Double-blind Placebo Controlled  ,3 months,30,4 F: 23 M,3-10 y,50 mg L-cartinine/kg bodyweight/day,,"Childhood Autism Rating Scale (CARS), hand muscle testing, and modified clinical global impression (CGI) forms",Significantly improved clinical measurements over time. ,,"Serum free-carnitine. Autism Treatment Evaluation Checklist (ATEC), treatment adherence measurement (TAM), frequency and intensity of side effect rating (FISER)/global rating of side effect burden (GRSEB)/patient report of incidence of side effects (PRISE) forms","""Significant correlations between increasing serum free-carnitine levels and positive outcomes on clinical measurements""",Well tolerated. Side effects included irritability and/or stomach discomfort. ,Minimal AEs.,"n=4 L-Carnitine; 1 AE, 2 non-compliance, 1 lost to follow-up ",21 White; 6 'minorities',,High risk - Participants were assigned to groups with a coin flip by a study investigator. This investigator was not involved in efficacy measurements,"Unclear risk - Participants were shipped either placebo or levocarnitine. No statements on the blinding of formulation of the placebo or levocarnitine (i.e. taste, shape, color, etc..)",Low risk - Assessors were blinded,Low risk - Participants and clinicians were blinded. ,Low risk - All baseline and endpoint scores on all measures reported. ,Low risk - All data reported. ,
Lovastatin & parent implemented language intervention (PILI),,,"Thurman, Angela",,,April 2020,Journal of Neurodevelopmental Disorders,Lovastatin (RPCT) & open-label PILI,20 weeks,32 (30 analyzed),28 M: 2 F,,max: 40 mg/d,"Language, nonverbal cognition",3 language samples (storytelling); ADOS-2; Leiter-R; PPVT-4; EVT-2,,Maladaptive behavior,RBS-R; ABC-C total,,,,n=2,24 Caucasian; 4 Hispanic; 1 African American; 1 Asian,,,,,,,,
Lurasidone,No,No,"Loebel, Antony",,Sponsored by Sunovion Pharmaceuticals,"December 11, 2015",Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled  - Fixed dose,6 weeks,150,121 M: 29 F,6-17 y; Mean: 11 y,20 mg/d or 60 mg/d,"Irritability, aggression, and SIB","Irritability, agitation, and/or self-injurous bx. Measured by the ABC-I",No change between tx groups for ABC-I scores. Not effacacious in short term tx of moderate-to-severe irritability. ,Obsessive compulsive behaviors.,CGI-I; CGI-S; CY-BOCS Compulsions; CGSQ global strain,"""Significantly greater improvement was observed at endpoint on the CGI-I scale for the lurasidone 20mg/day group compared with the placebo group"". No improvements on any of the other secondary outcome measures. ",Side effects included vomiting and somnolence. ,"Majority of the AEs were mild or moderate. 12% of AEs were severe in the lurasidone 20mg tx group. Serious treatment emergent Aes were arm fracture (n=3), increased irritability, and appendicitis. ","Discontinuation rates due to aes were: lurasidone 20mg/day, 4.1%; 60mg/day, 3.9%; and placebo, 8.2%",114 White; 24 Black; 10 Other,,,,,,,,
Mecamylamine,,,"Arnold, Eugene",,Dr. Aman and Dr. Arnold have received consulting honoraria and research support from multiple pharmaceutical companies.,2012,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled  - Pilot,14 weeks,20,17 M: 3 F,4-12 y; Mean: 7.4 y (SD: 2.55),"0.5 mg/d for 6 weeks - 2.5 mg for 2 weeks - then, 5 mg/d for 6 weeks.",,Ohio Autism Clinical Impressions Scale (OACIS) and OARS-4 ,"90% of the treatment group showed improvement, but only 40% sustained it. Better outcomes are more likely with lower mg/kg and longer medication duration.  Participants treated with a max dose of 0.13-0.15 mg/kg/d had a better outcome w/ sustained improvement, than those who regressed at doses ? 0.18mg/kg/d. ",,"Repetitive Behavior Scale, the Abberant Behavior Checklist, the Social Responsiveness Scale, and target symptom assessment",No significant improvements on any secondary measure. ,Well tolerated. Constipation was common. ,Safe. No dose reduction because of Aes,n=2 ,17 White; 2 Asian; 1 other,"""Mecamylamine appeared to be safe, but not very effective in autism. The suggestion of better results at lower doses and longer exposure warrants consideration for future trials. The next step would be exploration of a more specific a4b2 nAChR agonist, such as varenicline.""",,,,,,,
Melatonin,Yes,Yes,"Hayashi, M",0.1007/s10803-021-05139-w,Nobelpharma,"June 7, 2021",Journal of Autism & Developmental Disorders,RCT - Open-label,"56 days (14 d RCT, 52 d open-label)",196,121 M: 75 F,6-15 y; mean: 11 y,"1 mg, 4 mg, or placebo",Sleep onset latency,Sleep onset latency (SOL),"SOL shortened significantly in both melatonin groups compared to placebo group. However, SOL did not change in the subgroups: �female,�  �previous  history  of  ramelteon  treatment,�  and height ? 145 cm. 4-mg treatment shortened SOL in all participant subgroups. ",Sleep variables: Total sleep time (TST); sleep efficiency (SE); changes in aberrant behaviors,"Number of awakenings after sleep onset, wakening time after sleep onset, ABC","TST and the number of wakenings did not change in any melatonin groups. SE improved significantly in the 4-mg group. In the 1-mg melatonin group, wakening time after sleep onset extended significantly. No changes in ABC. ",Highest rates of AEs reported in the 4 mg group. Most common side effects were infections and infestations. ,Generally safe. 2 patients had serious worsening of irritability.,n=9,Not reported,"Study assessed efficacy of melatonin supplementation with adequate sleep hygeine. ""2 children were admitted to the hos-pital due to the abrupt deterioration of irritability�one of the aberrant behaviors of ASD�on the next day of the last medication. Hence, these episodes advert clinicians to be cautious when modi-fying the therapeutic intervention for children with ASD"".",Low risk - Computer generated randomization. ,Low risk - Independent third party ensured each treatment was indistinguishable. ,Low risk - All personnel in this study were blinded to treatment allocation,Low risk - Patients and clinicians were blinded to allocation and were given the same instructions. ,Low risk - All primary and secondary outcome results were reported,Low risk - Insignificant results reported. ,"Nobelpharma sponsored this study and provided the drugs for this study. However, risk of biases remain low, according to Cochrane's assessment. "
Memantine + Risperidone,Yes (memantine peppermint) ,,"Ghaleiha, Ali",https://doi.org/10.1017/S1461145712000880,None. ,5/1/2013,International Journal of Neuropsychopharmacology,Randomized Double-blind Placebo Controlled ,10 weeks,40,23 M: 17 F,4-12 y; mean: ~7.5 y,"risperidone- 2 mg/d & memantine- max: 15 mg/d for pt 10-40 kg, 20 mg/d for pt 40 kgo, or + placebo",Irritability,ABC-C Irritability,Significantly greater reduction in irritability scores in memantine tx group than placebo.,"Lethargy/social withdrawal, stereotypy, and hyperactivity/noncompliance",ABC-C: all other subscales. ,Significantly greater reduction in scores for hyperactivity and stereotypic bx.,Well tolerated. No differences in extrapyramidal symptom type or frequency between the two tx groups. ,,None,,https://academic.oup.com/ijnp/article/16/4/783/790133,,Medications were dispensed by the investigational drug pharmacist. ,,,,,
Memantine,,,"Valluripalli Soorya, Latha",10.1089/cap.2021.0010,,,Journal of Child and Adolescent Psychopharmacology,RCT - pilot,24 weeks,23,,6-12 y,,Neurocognitive effects,measures of apraxia and expressive language,No improvements in apraxia or expressive language.,"Neurocognitive measures (memory, adaptive behavior, overall cognitive functioning)",Narrative Memory-Recognition; ABC,Memantine treatment associated with improvement in verbal recognition memory and verbal IQ.,,,n=9,,,,,,,,,
Memantine ER,Yes (peppermint),,"Aman, Michael",,"Forest/Allergan, Shire, Bristol-Myers Squibb, BioMarin pharmaceuticals. ",2015,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled  ,12 weeks ,121,101 M: 20 F,6-12 years; Mean: 9 years,3-15 mg/d (based on body weight),Social behaviors. ,SRS total raw score,No significant differences between memantine and placebo tx groups.,,CATS-I total score and subscales; CCC-2; ,No significant differences in CATS-I or CCC-2 scores. ,"All treatment emergent AEs were mild to moderate severity, except for 3 in the memantine tx group (irritability, affective disorder, and choking).",One serious AE (mood/affective disorder) in memantine group unrelated to tx. ,n=17 (3 due to AE in memantine group),99 White; 11 Asian; 4 Black; 7 Other,,,,,,,,
Metformin hydrochloride (Riomet),Yes,,"Anagnastou, E",10.1001/jamapsychiatry.2016.1232,,August 2016,JAMA Psychiatry,Randomized Double-blind Placebo Controlled  ,16 weeks,60,45 M: 15 F,6-17 y; M= 12.8 y (SD: 2.7),500 mg BID for 6-9 y (M: 1000 mg/d); 800 mg BID for 10-17 y (M:1587 mg/d),Treatment of weight gain from atypical antipsychotic use,BMI z score,Metformin was superior to placebo in reducing weight gain. 11% of metformin treatment participants had 8-9% declines in BMI. ,Changes in body composition and metabolic variables,"Body variables: absolute and relative change in weight, absolute BMI, abdominal and hip circumference; fasting metabolic variables ",No significant changes in metabolic variables for metformin or placebo groups. ,"Abnormal feces, increase in GI AEs. ",No serious AEs related to the study drug,n=7 (5 metformin),4 Asian; 4 black or African; 50 white; 2 other/multiracial,"51 participants were obese, 8 overweight, 1 normal weight. Most participants were taking aripiprazole (23) or risperidone (31). https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2546510",Low risk - Randomization conducted using permuted blocks stratified by age group and random block sizes.,"Low risk - Metformin and placebo dispensed as liquid that matched in appearance, smell, and taste",Low risk - All treatment was double blinded. ,Low risk - All treatment was double blinded,Low risk - All baseline and endpoint data reported. ,Low risk - All baseline and endpoint data reported. ,autogenerated randomization ID email sent to site once pt enrolled
Methylphenidate,"Yes (grape, banana)","Chewable tablets (cherry, grape)","Aman, Michael; RUPP",,,"March 29, 2005",Arch Gen Psychiatry,RPCT - Crossover,"13 weeks. 1-wk test-dose phase, 4-wk randomized, placebo-controlled, double blind crossover phase, and 8-wk open-label continuation.",66,59 M: 7 F,5-14 y ,Weight-dependent dosing -  Low dose: 2.5-5.0 mg TID; Mediium dose: 2.5-10.0 mg TID; high dose: 5.0-20.0 TID. See note for more info on dosage.,Hyperactivity,Teacher-rated hyperactivity subscale of ABC,Methylphenidate was superior to placebo on improvements in the primary outcome measure with small to medium effect sizes (0.20-0.54),"Hyperactivity, stereotypy, inappropriate speech, lethargy/social withdrawal.","Parent-rated ABC hyperactivity subscale, and other ABC subscales; rate of 'responders' (classified by much/very improved on CGI-I and 30% decrease in ABC hyperactivity scores)",Significant main effect on parent-rated ABC hyperactivity scale scores (F=6.10; P<.001). Parent-rated lethargy/social withdrawal subscale scores were significantly worse than placebo. Improvements in stereotypy and inappropriate speech at medium dosage. 49% of subjects were responders.,"Common side effects included decreased appetite, difficulty falling asleep, irritability, and outbursts. Intolerable AEs did lead to 7 dropouts.",,"n=7 (3 high dose, 3 medium dose, 1 low dose)",48 white; 9 black/African American; 6 Asian; 3 Hispanic or Latino,"Methylphenidate dosing based on weight. The mean weight of pts was 30.4 kg (SD: 14.3 kg). Doses were administered 3 times per day (8 am, 12 pm, 4 pm). Low dose - 0.125 mg/kg, medium dose - 0.250 mg/kd, high dose - 0.500 mg/kg, per dose. ""Methylphenidate was consistently more efficacious in improving inattention, distractability, hyperactivity, and impulsivity than placebo was, as rated by the ABC hyperactivity scale... small to medium magnitude of response.""","High/unclear risk -  Centrally generated randomization that was balanced by site. There were 2 exceptions to the complete randomized design. ""subjects who could not tolerate the high dosage of methylphenidate received the medium dose twice... and the high dose could not follow the placebo...""",Unclear risk- Method of allocation not reported.,"Unclear risk- Medication form, taste, and color not reported. Methylphenidate and placebo capsules were compounded by an FDA approved pharmacy at the University of Iowa, and shipped to an investigational pharmacist at each site. ","Low risk - Clinicians, patients, and caregiver were blinded to treatment assignment. Prescribing and rating clinician were kept blind to possible treatment related AEs.",Unclear risk - CGI-I scores not reported.,"Unclear risk - All parent-rated and teacher-rated ABC scores and effect sizes were noted. Including, the worsening of lethargy/social withdrawal. No CGI-I scores.","49% of methylphenidate tx participants were rated as responders, though the CGI-I scores and other ABC subscale scores were not reported. The only quantitative data to support the respondent claim would be the ABC hyperactivity scores."
Methylphenidate,"Yes (grape, banana)","Chewable tablets (cherry, grape)","Handen, BL",PUBMED: 11055460,No conflicts of interest,2000,Journal of Autism & Developmental Disorders,"double-blind, randomized, placebo-controlled, cross-over",3 weeks,13,10 M: 3 F,5.6-11.2 y (m: 7.4 y),0.3 mg/kg and 0.6 mg/kg 2-3x per day,Hyperactivity,Conners' Teacher Rating Scale (CTRS); IOWA Conners' Teacher Rating Scale ,,Severity,CARS; ABC,,,,n=1,7 African American; 4 white; 2 Latino,,Unclear risk - method of sequence generation not described,unclear risk - method of concealment not reported,low risk - All outcome assessors blinded,"unclear risk - All parents and participants were blinded. However, it was not reported if participants had taken methylphenidate before.",Unclear risk - Assessment measures data not reported. ,"High risk - Parent rated questionnaires were not reported, only teacher rated assessments.",
Methylphenidate,"Yes (grape, banana)","Chewable tablets (cherry, grape)","Pearson, DA",https://doi.org/10.1089/cap.2012.0096,The authors report having received financial support from pharmaceutical companies (including manufacturers of pharmaceuticals for behavioral syndromes),2013,Journal of Child and Adolescent Psychopharmacology,"double-blind, placebo-controlled, cross-over",4 weeks,24,19 M: 5 F,"7.1-12.7 y (m: 8.8 y, SD: 1.7)",,ADHD symptoms,Conners' Teacher Rating Scale - Revised - Short Form (CTRS-R-SF),Methylphenidate decreased hyperactive and impulsive behavior at school and at home. ,ADHD symptoms,"Swanson, Nolan, and Pelham Questionnaire (SNAP-IV-Teacher); ADD-H Comprehensive Teacher Rating Scale (ACTeRS); Conner's Global Index-Teacher and Parent; ABC-Teacher; CGI-Improvement and CGI-severity); Conners' Parent Rating Scale (CPRS-R); Parent SNAP-IV; Parent ABC; Parent VAS","Methylphenidate treatment decreased hyperactive and impulsive behavior at school and home. Treatment also decreased inattentive and oppositional behavior at home, as well as, increased social skills. ","side effects ""similar to those in typically developing children with ADHD""  - well tolerated",Generally safe,n=0,13 white; 5 Hispanic; 4 African-American; 1 Asian; 1 multiple races,,unclear risk - Not randomized.,unclear risk - Unclear how sequences were allocated. ,"Unclear risk - Over half of the patients had taken methylphenidate before, so parent assessors had known effects of this drug. ",unclear risk - Clinicians and participants were blinded to dosages during trial. It is not stated if parents were blinded. The study physician and psychologist were unblinded during test-dose period. ,low risk - Outcomes reported for all participants.,low risk - All negative side effects and outcome data was reported. ,The authors have financial support from pharmaceutical companies that manufacture medication for behavioural syndromes.
Methylphenidate,Yes,"Chewable tablets (cherry, grape)","Quintana, H",PUBMED: 7559293,No conflicts of interest ,1995,Journal of Autism and Developmental Disorders,Double blind - crossover,6 weeks,10,6 M: 4 F,7-11 y (m: 8.5 y SD: 1.3),10-20 mg BID,Not specified,"CARS, ABC, CTQ hyperactivity, CAPQ",Methylphenidate treatment showed modest but statistically significant improvement in hyperactivity.,,AIMS,,No significant side effects,Generally safe,n=0,Not reported,,Unclear risk - Not described,"Unclear risk - Method of concealment not described, but reported as ""randomly assigned""","Low risk - Clinicians, children and parents were blinded","Low risk - Clinicians, children, and parents were blinded",Low risk,High risk - CARS results not reported. ,
Mirtazapine,No,Yes,"McDougle, Christopher J. ",,,Mar-22,Neuropsychopharmacology,RCT,10 week,30,,5-17,7.5-45 mg/d,Anxiety,PARS; CGI-I,Significant within group decrease in anxiety on PARS. No improvement on CGI. ,,,,,,,,,,,,,,,
"Oxytocin, multiple dose",,,"Bernaerts, Sylvie",10.1186/s13229-020-0313-1,No conflicts of interest. ,"January 15, 2020",BioMed Central,"RPCT - Pilot, parallel design ",4 weeks of treatment; 4 week follow up and 1 yr follow up (60 weeks total),40,100% M,Mean: 24.5 years ,24 IU qD ,Social behaviors. ,SRS-A (self and informant),No treatment specific effects on core social behaviors as measured by SRS-A,Reactivity and avoidance. ,"RBS-R, SAAM, IPPA, WHO-QOL","Avoidance was lower in the oxytocin group for T1, T2, and T3. RBS-R scores were lower at T1, T2, and T3. ",Increased visor for the oxt treatment group. Significant decrease in tension and fatigue at T1 for both groups. ,"Minimal, non treatment specific side effects. ",n=1 oxytocin; n=8 for one year follow up ,not reported,"This study assesses the long-term effects of intranasal oxytocin treatment. ""Long-term beneficial effects on repetitive behaviors and feelings of avoidance are promising and suggestive of a therapeutic potential of oxytocin treatment for ASD.""",,,,,,,
N-Acetylcysteine (NAC),Yes,Yes,"Dean, Olivia ",,No conflicts of interest reported. ,"June 17, 2016",Australian and New Zealand Journal of Psychiatry,"RPCT, Parallel ",6 months,102,79 M: 19 F,3.1-9.9 y,500 mg/d,Social and repetitive behaviors. ,"Social Responsiveness Scale, Children's Communication Checklist, and the Repetitive Behavior Scale-Revised",No differences in the scores for NAC and placebo groups. ,Social behaviors.," Vineland Adaptive Behavior Scales, Social Communication Questionnaire, and clinician-administered Autism Diagnostic Observation Schedule",No differences in the scores for NAC and placebo groups. ,,No significant difference between the treatment and placebo groups in occurrence and severity of adverse events. ,,,"Can only access the abstract, so some data is unknown. ""This study failed to demonstrate any benefit of adjunctive N-acetylcysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be cofounders.""",,,,,,,
Naltrexone,No,No,"Campbell, Magda",,No conflicts of interest reported. ,1993,Journal of the American Academy of Child and Adolescent Psychiatry,Randomized Double-blind Placebo Controlled ,6 weeks,41,,2.9-7.8 y,,Aggression and self injurous behaviors (SIB).,Aggression and self injurous bx (SIB).,No improvements in SIB or core features of ASD.,Hyperactivity,CPRS,Significant improvement in hyperactivity.,Well tolerated.,,,,"""Naltrexone does not appear to have robust effects targeting ASD-Associated aggression, although it may have some impact on hyperactivity in the population"" (Fitzpatrick)",,,,,,,
Naltrexone,No,No,"Campbell, Magda",,,,Journal of the American Academy of Child and Adolescent Psychiatry ,Randomized Double-blind Placebo Controlled ,6 weeks,41,21 M: 3 F,2.9-7.8 y,1.0 mg/kg/d,Attention and hyperactivity.,Attention and discrimination learning.,"Significant decrease in hyperactivity on three measures, hyperactivity factor, restless/overactive item on the PTQ, and activity on the computer.",,,,"Minimal side effects, which included, excessive sedation, decreased appetite, and vomiting.",,,"21 white; 3 African-American (""Race was not associated with socioeconomic status in this sample.""",,,,,,,,
Olanzapine,,Yes,"Hollander, Eric",,,2006,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled   - Pilot,8 weeks,11,,6-14 y,7.5-12.5 mg/d; mean: 10 (SD: 2.4 mg/d),Irritability,CGI-I,Olanzapine was superior to placebo on CGI-I scores.,Stereotypic and repetitive behaviors,CY-BOCS and OAS-M,No differences between tx groups.,Weight gain and sedation. Well tolerated.,Generally safe. No dyskinesia or EPS.,n=3,,Very small treatment group.,,,,,,,
Omega-3 Fatty Acids,,,"Bent, Stephen",,No conflicts of interest reported. ,"August 4, 2010",Springer Link,Randomized Double-blind Placebo Controlled  ,12 weeks,27,Not reported. ,3-8 years; Mean 5.8 years,1.3 g/d,Hyperactivity,ABC Hyperactivity,No statistically significant changes in scores. Trends could show small to moderate improvements in hyperactivity with Omega fatty acids. ,,"ABC Irritability, Stereotypy, Lethargy, Inappropriate speech; PPVT; EVT; SRS; BASC; ",No statistically significant changes in scores. ,"Well tolerated. AEs included rash, upper respiratory infection, and GI issues. ",No treatment related serious AEs. ,n=8,Not reported. ,,,,,,,,
"N-Acetylcysteine (NAC), oral",Yes,Yes,"Hardan, Antonio",10.1016/j.biopsych.2012.01.014.,"Bristol-Myers Squibb Co., Forest Pharmaceuticals, Shire Development, Inc. and Bioadvantex, Inc. ","June 1, 2012",Biological Psychiatry ,"RPCT, Pilot",12 weeks,33,31 M: 2 F,"3-10 y, Mean: 7 y","max: 2700mg/d; 900mg/d for the first 4 weeks, 900mg BID  for the next 4 weeks; 900mg 3x/day for the remainder.  ",Irritability,Aberrant Behavior Checklist-Irritability subscale (ABC-I) and DOTES,NAC treatment resulted in significant improvements in irritability scores. ,Social and repetitive/stereotypic behaviors. ,"ABC-Stereotypy subscale, Repetitive Behavior Scale - Revised (RBS-R), Social Responsiveness Scale (SRS), and CGI-I ",NAC treatment resulted in improvement of stereotypic/repetitive behvaior on the ABC and significant improvement on the RBS-Stereotypies. No significant difference in the SRS. ,Well tolerated with limited side effects. Most AEs were gastrointenstinal. ,Minimal AEs. One participant experienced worsening of agitation and irritability. ,n=4 ,"""There were no differences between the placebo group and active group on any of the demographic and clinical baseline measures.""",,,,,,,,
Oxytocin,n/a,n/a,"Sikich, Linmarie",10.1056/NEJMoa2103583,No conflcits of interest,October 2021,The New England Journal of Medicine,RCT,24 weeks,277,142 M: 35 F,3-17 y (mean: 10.4 y SD: 4.0),48 IU-80 IU daily; mean maximal daily dose: 69 SD: 16.9 IU,Social functioning,ABC modified Social Withdrawal subscale (ABC-mSW),No significant difference between treatment grooups.,Social functioning,SRS-2 Social Motivation subscale (SRS-2-SM); Sociability Factor; and SB5 Abbreviated IQ,No significant difference between treatment groups.,"Higher incidences of increased appetite, increased energy, restlessness, increased thirst, and inattention in the oxytocin group",1 serious AE related to oxytocin (sedation while driving),"n=27 (14 OXT, 13 placebo)",204 white; 23 black; 23 Asian; 23 multiracial; 28 Hispanic,Flexible dose strategy used could be a limitation,low risk - Centralized randomization table,"Low risk - Drug container system, volume, labeling, and other features were matched.",Low risk - All outcome assessors were blinded.,Low risk - Clinicians and participants were blinded.,Low risk - All outcome data provided.,Low risk - All outcomes reported. Negative and insignificant outcomes reported.,
Oxytocin ,n/a,n/a,"Yamasue, Hidenori",10.1038/s41380-018-0097-2,,2020,Molecular Psychiatry,Randomized Double-blind Placebo Controlled  ,6 weeks,106,,18-48 y,48 IU/d,,ADOS; oxytocin plasma levels,"Both placebo and oxytocin treatment groups had reduced scores, no treatment difference. Plasma oxytocin elevated over course of trial in oxt treatment group compared with placebo group.",,"ADOS repetitive behavior, duration of gaze fixation",Oxt treatment reduced ADOS repetitive behavior scores and duration of gaze fixation in social regions. ,Well tolerated. One pt had temporary gynecomastia during Oxt treatment. ,,,,,,,,,,,
Oxytocin + Probiotic,,,"Kong, Xue-Jun",10.3390/nu13051552,,May 2021,BMC,Randomized Double-blind Placebo Controlled  - Pilot,,35,26 M: 9 F,3-20 y; Mean:10.30 y,Oxytocin (titrated to max dose of 32 IU/d) + PS128 probiotic ( 6x10^10 CFUs) or + placebo,Social interest & interaction; core ASD symptoms,caregiver-rated Social Responsiveness Scale (SRS) & caregiver-rated Aberrant Behavior Checklist (ABC),"The probiotic + OXT group had improvements on ABC and SRS. Most improvement was on the ABC total and stereotyped behavior scores, and the SRS cognition subscale. ","GI symptoms, global functioning, and blood samples",Blood sample collection & circulating biomarker analysis; GI severity index (GSI); Clinical Global Impression (CGI),No change in GI severity. The combination treatment group showed significant improvement of CGI. ,,,n=4,28 Asian; 1 Hispanic; 6 White,,Low risk - computer generated,Low risk - Drug containers and capsules were identical in appearance and prepared by pharmacy. ,Low risk - Assessors were blinded to treatment allocation,Low risk - Participants blinded to treatment allocation,,,
Paliperidone,No,No,"Stigler, Kimberly A.",,,"May 3, 2012",Psychopharmacology,,,30,,,,,,,,,,,,,,,,,,,,,
Pentoxifylline + Risperidone,,,"Akhondzadeh, Shahin",,,2009,Progress in Neuro-Psychopharmacology and Biological Psychiatry,Randomized Double-blind Placebo Controlled ,10 weeks,40,,4-12 y,"Risperidone- 3 mg/d + pentoxifylline- 600 mg/d, or + placebo",Core symptoms of ASD,ABC-C,"Pentoxifylline tx group had greater reduction in subscales for irritability, lethargy/social withdrawal, stereotypic bx, hyperactivity/noncompliance, inappropriate speech",,none,n/a,,,,,https://www.sciencedirect.com/science/article/abs/pii/S0278584609003091,,,,,,,
Piracetam + Risperidone,yes both,yes (risperidone),"Akhondzadeh, Shahin",,None reported. ,"October 11, 2007",Child Psychiatry and Human Development,Randomized Double-blind Placebo Controlled  ,10 weeks ,40,30 M: 10 F,3-11 y; Mean: 6.8 y,Risperidone: 2 mg/d for children 10-40 kg; 3 mg/d for children 40 kgo; Piracetam: up to 800 mg/d,Core symptoms of ASD,ABC-C Rating Scale (total score) ,Scores improved with piracetam ,,None,N/A,"There were no differences in side effects or the frequency between treatment groups. The most common side effects were daytime and morning drowsniess, and increased appetite. ",No serious or severe side effects. ,None,Not reported.,"Risperidone adjuvant piracetam proved to show markedly greater improvements in ASD symptoms than risperidone by itself. ""The results suggest that a combination of atypical antipsychotic medications and a glutamate agent such as piracetam, might have increase synergistic effects..."" when treating disruptive symptoms in ASD. ",,,,,,,
Prebiotic + exclusion diet,n/a,n/a,"Grimaldi, R.",https://doi.org/10.1186/s40168-018-0523-3,Clasado Research Services Ltd (provided prebiotic and funding),2018,Microbiome,RCT,6 weeks,41,31 M: 10 F,4-11 y; mean: 7.7 y,"prebiotic B-GOS mixture (Bimuno, 80% GOS content): 1.8 g, and exclusion dieet (gluten and casein free)",Social behaviors and anxiety,ATEC (anti-sociability); AQ (social skills); EQ-Sq; SCAS-P,"Overall severity of behavioral traits were not significantly affected. However, reduced anti-social behavior in concurrent with an improvement in social skill scores were seen in children on the combination of exclusion diet and prebiotics. ","GI Symptoms, urine spectra profiles, fecal samples, sleep","abdominal pain, bowel movement, bloating, flatulence, and stool form; urine samples; stool samples; sleep diary",B-GOS led to significant alterations in urine spectra profiles and metabolic shifts in fecal samples. No significant change in GI symptoms or sleep patterns. ,Well tolerated - minor severity diarrhea,Generally safe - no serious AEs,n=4,Not reported,"Four arm trial - exclusion diet + B-GOS, exclusion diet + placebo, unrestricted diet + B-GOS, unrestricted diet + placebo",Low risk,Low risk,Low risk,Low risk,High risk,Low risk,
Probiotics,,,"Arnold, Eugene ",,,"November 9, 2019",Journal of Child and Adolescent Psychopharmacology,RPCT - Pilot ,8 weeks ,13,,3-12 years,,GI symptoms.,PedsQL GI module,,,"Gut microbiota analysis, PRAS-ASD, and parent-selected target symptoms",,,,,,,,,,,,,
Probiotics (visbiome/vivomixx),,,"Arnold, Eugene",,,2019,Journal of Child and Adolescent Psychopharmacology,RPCT- Pilot,19 weeks,13,6 M: 4 F,3-12 y; Mean: 8.8 y,,Gastrointestinal symptoms.,Pediatric Quality of Life Inventory GI Module,,,"gut microbiota analysis, the parent-rated anxiety scale for ASD, and parent-selected target symptoms",,"Decreased appetite, enuresis, encopresis",,n=3,5 Black; 3 white; 2 other/multiracial,,,,,,,,
Probiotics (visbiome/vivomixx),,,"Santocchi, Elisa",https://doi.org/10.3389/fpsyt.2020.550593,None,September 2020,Frontiers in Psychiatry,RCT,6 months,85,84% M,18-72 mo; mean: 4.2 y,"2 packets/day in first month, then 1 packet/day for the remainder",Core symptoms and GI symptoms,ADOS-CSS,No differences in ADOS-CSS.,"Adaptive functioning, social behaviors, severity of GI symptoms, restricted and repetitive behaviors","VABS-II; Total GSI; SCQ; RBS-R; CBCL 1, 5-5; PSI; Plasma levels of leptin, TNF-a, IL-6, PAI-1, and fecal calprotectin levels","Greater improvement in GI symptoms, adaptive functioning, and sensory profiles with probiotic supplementation. ",,,,,,Low risk - Computer generated randomization,Low risk - Placebo and probiotic packaging and organoleptic characteristics were identical. Administration instructions were the same.,Low risk - All outcome assessors were blinded.,"Low risk - Clinicians, patients, and families all blinded.",Low risk - All assessment scores reported and all adverse effects reported in statistics table.,"Low risk - All outcomes reported, included significant and insignificant.",
Probiotics,,,Parracho,,,2010,,RCT - crossover,3 weeks,62,,4-16 y,L. plantarum WCFSI 45 billion CFU/capsule,Behavioral symptoms,"DBC-P, TBPS",,GI Symptoms,,,,,,,,Low risk,,,,,,
Probiotics (Lactobacillus plantarum PS128),No,No,"Liu, Yen-Wenn",10.3390/nu11040820,"Bened Biomedical Co., Ltd.",April 2019,Nutrients,RCT,4 weeks,80,All male,7-15 y (mean: 10.01 SD: 2.32),3 x 10^10 CFU/capsule of PS128,Core symptoms,"ABC-Taiwan version, SRS, CBCL","Subjects in the PS128 group showed nominal improvements in ABC-T-body and object use, SRS-total score, CBCL-anxiety and CBCL-rule breaking behavior. No significant between-group differences in most ABC-T subscales or CBCL subscales.",Core symptoms,SNAP-IV Chinese version; CGI-I,"PS128 group showed nominal improvements in SNAP-IV-hyperactivity/impulsivity, oppoition/defiance, and SNAP-IV-total score (greater improvement in younger subjects, 7-12 yrs). No between-group difference in CGI-I or SNAP-IV inattention.",No AEs reported,Generally safe,n=9,,,"Low risk - Randomized using treatment codes, performed by a research assistant who had no contact with participants","Low risk - PS128 and placebo capsules were identical in taste, appearance, and storage.",Low risk - All outcome assessors were blinded.,Low risk - Clinicians and participants were blinded,Low risk - All baseline and endpoint outcome data reported.,"Low risk - All outcome data reported, including insignificant findings.","Bened Biomedical Co provided PS128. Funded by Bened Biomedical Co., Ltd., one author/investigator owns stock in Bened Biomedical Co., Ltd. "
"Melatonin, Prolonged Release ",,,"Schroder, Carmen M.",10.1089/cap.2018.0020,,"May 11, 2019",Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled  ,13 weeks,125,92 M: 33 F,2-17.5 y; Mean: 8.7 y (SD: 4.15),2-5 mg,Sleep habits and quality of life.,Strengths and Difficulties Questionaire; Caregiver's quality of life,"Prolonged release melatonin tx resulted in significant improvents in externalizing bx, Caregivers quality of life improved and correlated with the change in total SDQ.",,,,,,n=24 (7 PedPRM),112 white; 9 black or african american; 6 other; 2 Asian,"""PedPRM alleviates insomnia related difficulties, particularly externalizing behavior in the children, subsequently improving caregivers' quality of life."" ",,,,,,,
"Melatonin, Prolonged-release ",,,"Gringras, Paul",,"Neurim Pharmaceuticals, Akili, Alcobra, KemPharm, Pfizer, Purdue, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Takeda, Teva, Touchpoint, Tris, Validus, and WebMD",November 2017,Journal of the American Academy of Child and Adolescent Psychiatry ,Randomized Double-blind Placebo Controlled  ,13 weeks,125,92 M: 33 F,2-17 y; Mean: 8.7 (SD: 4.15 y),2-5 mg,Sleep habits.,SND-reported total sleep time,Melatonin treated participants slept an average of 57.5 minutes longer than placebo. ,Sleep latency. ,"Sleep latency, duration of wake after sleep onset, mean number of awakenings, and mean longest sleep episode ","Sleep latency decreased by 39.6 minutes with PedPRM, without earlier wake up time. ",Few and mild AEs. Headaches and daytime somnolence increased in melatonin tx group. ,"Severe AEs reported by 13 pts in PedPRM group, these included agitation, fatigue and mood swings. ",,112 white; 9 black; 2 Asian; 6 other,,,,,,,,
Propranolol,Yes,No,"Williams, Daniel T. ",,Not reported,1982,Journal of the American Academy of Child and Adolescent Psychiatry,Retrospective study,2.5 years,30,26 M: 4 F,"7-35 y (11 children, 15 adolescents, 4 adults)",50-960 mg/d; mean: 160 mg/d,Rage outbursts,Pattern of uncontrolled rage outbursts,Over 75% of patients showed marked improvement w/ usage of propranolol,Uncontrolled seizures,Uncontrolled seizures,Only 1 out of 11 patients with seizures did propranolol show improvement. ,"Somnolence, lethargy, hypotension. ",One serious AE of bradycardia. One patient experienced extreme worsening depression which was alleviated with lower dosage. ,,,,,,,,,,
Propranolol or nadolol,Yes,No,"Narayanan, Apanth",10.1007/s11682-010-9098-8,,2011,Brain Imaging and Behavior,Pilot open label imaging study,,,,,,,,,,,,,,,,,,,,,,,
rTMS,n/a,n/a,"Ameis, Stephanie",doi:10.1016/j.brs.2020.01.007.,Brainsway Ltd,2020,Brain Stimulation,RCT - sham controlled,4-weeks (20-session),40,28 M: 12 F,16-35 y ,20 Hz rTMS targeting DLPFC,Executive functioning,"BRIEF-SR, BRIEF-A, BRIEF-MCI, CANTAB SWM task",Baseline SWM total errors and BRIEF-MCI scores predicted treatment outcome. ,Potential moderators,VABS-II and gender,Baseline adaptive functioning and gender possibly moderated effects of rTMS. More severe adaptive functioning deficits at baseline showed more improvement with rTMS. Spatial working memory showed greater improvement in females than in males. ,No group differences in side effects,No severe AE,n=2 (in rTMS group after 1-2 sessions),,,Low risk - computer-generated 1:1 allocation with a random number that a research assistant concealed ,"Low risk - Allocation concealed using sealed, opaque envelopes. ","low risk - Study investigators, clinical/cognitive raters were blinded","Low risk (?) - Clinicians and participants remained blinded. rTMS technicians were aware of group assignment, but were not involved in allocation or clinical/cognitive assessment. ",No - all data reported,No - Insignificant outcomes were reported.,
Repetitive transcranial magnetic stimulation (rTMS),n/a,n/a,"Ameis, Stephanie",,No conflicts of interest. ,2017,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled  ,4 weeks,40,Not reported. ,16-35 years,20 Hz rTMS applied to dorsolateral prefontal cortex,,Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task,,,,,No seizures. Side effects were transient and mild. ,Generally safe. No lasting adverse effects. Inadvertent induction of a seizure are monitered. ,,,All psychiatric medications were continued throughout trial. ,,,,,,,
Resveratrol + risperidone,yes both,Yes (risperidone),"Hendouei, Fatemeh",10.1111/jcpt.13076,No conflicts of interest,2020,Journal of Clinical Pharmacy and Therapeutics,Randomized Double-blind Placebo Controlled ,10 weeks,62,50 M: 12 F,mean (resveratrol): 7.8 y (SD:2.1); mean (placebo): 8.1 y (SD: 1.9),"risperidone: and resveratrol: 250 mg BID, or plus placebo",Irritability,ABC irritability,No time x treatment differences in resveratrol and placebo groups. ,"Hyperactivity/non-compliance, lethargy/social withdrawal, stereotypy, and inappropriate speech",ABC-C (all subscales),"Significant time x treatment effect on hyperactivity/non-compliance for the resveratrol group compared to placebo. No time x treatment differences in ABC lethargy/social withdrawal, stereotypic behaviour, and imappropriate speech subscales.","No differences in rates or severity of AEs between groups.Restlessness, constipation, diarrhoea (resveratrol), increased appetite (placebo)",No serious AEs,n=0,Not reported,,Low risk - Randomized computer generated codes assigned to each patient.,"Low risk - Assignments in confidential sealed envelopes until study endpoint. Placebo and resveratrol were identical in shape, size, colour, and taste.",Low risk - All outcome assessors were blinded.,"Low risk - Clinicians, patients, and families all blinded.",Low risk - All assessment scores reported and all adverse effects reported in statistics table.,"Low risk - All outcomes reported, included significant and insignificant.",Overall low risk
Riluzole,Yes,No,"Wink, Logan K.",,No conflicts of interest. ,"Aprill 11, 2018",Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled   - Crossover,12 weeks ,8,7 M:1 F,13.1-18.45 y; mean: 16.02 y,200 mg/d,Irritability,ABC-Irritability,No significant treatment effect on irritability.,,,,Well tolerated.,Generally safe. No serious Aes,n=1 (worsening aggressive bx),5 white; 1 African-American; 1 hispanic,,,,,,,,
Riluzole + Risperidone,Yes,Yes (risperidone),"Ghaleiha, Ali",,No conflicts of interest or commercial funding.,"July 3, 2013",Pediatric Drugs,Randomized Double-blind Placebo Controlled ,10 weeks,49,33 M: 7 F,5-12 y; mean: 7.6-8.4 y,Risperidone- 2 or 3 mg/d (both based on body weight) + Riluzole- 50 or 100 mg/d; or + placebo,Irritability,ABC-C Irritability score,There was a significantly greater improvement in ABC-C irritability scores in the riluzole tx group (p=0.03). ,"Lethargy/social withdrawal, stereotypy, and hyperactivity/noncompliance",Other ABC-C subscales and CGI-I scores,"The riluzole group showed greater improvement on ABC-C lethargy/social withdrawal (p=0.02), stereotypic behavior (p=0.03), and hyperactivity/non-compliance (p=0.005) scales. The riluzole pts also showed more clinical improvement on CGI-I. No improvement on the inappropriate speech scale. ",Generally well tolerated. The riluzole tx group had more frequent increases in appetite and weight gain. The frequency of other side effects were the same in both tx groups. Common AEs included morning drowsiness and increased salivation. ,"Generally safe. However, riluzole added to risperidone can increase chances of increased bodyweight and appetite in pts.",n=9 (5 riluzole),Not reported. No significant differences between tx group baseline characteristics.,"""...Significance was reached on the irritability and hyperactivity/noncompliance subscales scores by the middle of the trial, suggesting an early impact of riluzole on behavioral disturbances. This finding is congruent with the formerly evident concept that pharmacological treatments are more efficient in ameliorating comorbid symptoms than in ameliorating core deficits in patients with autism"". ",,,,,,,
Risperidone,Yes,yes,"Aman, Michael",10.1089/cap.2007.0133,"Affiliations with Bristol-Meyers Squibb Co, Johnson and Johnson, Forest Research Institute, Neuropharm, Supernus, Novartis, Organon, Janssen, and McNeil.",2008,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled ,8 weeks,38,9 F: 29 M,5-18 y,0.5-3.5 mg/d,Cognition,Sustained attention; hand-eye coordination; verbal learning; and spatial memory. Cancellation Task and Verbal Learning Task scores. ,"There were no declines in attention, hand-eye coordination, or short term verbal memory. Significant improvement in the Cancellation Task and Verbal Learning Task scores in the treated group. ",,None,N/A,None Reported,None reported,,81.57% White; 5.26% Black; 7.89% Asian/Pacific Islander; 5.26% Hispanic,"Affiliations with Janssen, who manufactures risperidone and is also the company who assigned the drug order.","Unclear Risk - The study does not report how the randomization was carried out, or even that the sequence was randomized. ",Unclear risk - method of allocation not reported,"Unclear risk - ""Matched placebo and risperidone were provided by the manufacturer (Janssen Pharmaceuticals) in tablet form."" Tablet form, color, or taste was not reported. Flexible dosing, concealment for differences in dosage not described. ",,Low risk - Data for all primary outcome measures were reported in a table with the baseline scores. ,Low risk,Conflicts of interest include Janssen (manufacturer of risperidone) and Johnson & Johnson.
Risperidone,Yes,yes,"Kent, Justine",10.1007/s10803-012-1723-5,"Janssen, Bristol-Myers Squibb, Pfizer, Purdue Pharma, Forest",December 2012,Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled ,,96,,5-17 y,"low dose: 0.125�mg/d [20 to <45�kg], 0.175�mg/d [>45�kg]; or high-dose: 1.25�mg/day [20 to <45�kg], 1.75�mg/day [>45�kg]) or placebo",Irritability,ABC irritability subscale,High dose risperidone treatment group had significant improvement in scores. Low dose and placebo had no difference in baseline to endpoint scores.,Severity and repetitive/stereotypic behaviors,CGI severity; YBOCS,"CGI and YBOCS scores improved significantly in the high dose risperidone group, no improvement in the low dose or placebo groups. ","Increased appetite, somnolence, and sedation in the high dose risperidone group. ",,,,,,,,,,,
Risperidone ,Yes,yes,"McCracken, James ",,No conflicts of interest. ,"August 1, 2002",The New England Journal of Medicine,Randomized Double-blind Placebo Controlled ,8 weeks ,101,82 M: 19 F,5-17 y; Mean: 8.8 y,0.5-3.5 mg/d; Mean: 1.8 mg/d,Irritability,Abberant Behavior Checklist- Irritability subscale (ABC-I),Treatment with risperidone resulted in a higher rate of reduction in the irritability subscore than placebo. ,Global severity,Clinical Global Impressions-Improvement (CGI-I Score); VABS,The rate of positive response was higher in the risperidone group than the placebo. ,Well tolerated. Mild to moderate AEs. Common side effects included weight gain. ,"One severe headache. However, 'the short period of this trial limits inferences about adverse effects such as tardive dyskinesia'. ",6% Risperidone; 35% placebo ,Not reported. , ,High risk - randomization method not reported,Unclear risk - method of allocation concealment not reported,"Unclear risk - Study does not state outcome assessors were blinded, only states that clinicians and participants were blinded",Low risk - Clinicians and participants were blinded to allocation,Unclear risk - All measures baseline scores were reported. CGI and VABS endpoing scores not reported in results table. ,"Unclear risk - Endpoint scores for ABC irritability were the only reported in the table, though baseline scores for CGI, VABS, and ABC were reported. No endpoint data on VABS to know if there was worsening of scores or insignificant changes. ",
Risperidone + Buspirone,Yes (risperidone) No (buspirone),Yes (risperidone) No (buspirone),"Ghanizadeh, Ahmad",,,January 2015,Pediatric Neurology,Randomized Double-blind Placebo Controlled ,8 weeks ,40,,,"Buspirone: 10 mg/d for pts under 40 kg, and 20 mg/d for pts 40 kgo; Risperidone: 2 mg/d for pts under 40 kg, and 3 mg/d for pts 40 kgo",Irritability,ABC-C score,Irritability scores decreased for both treatment groups. More pts had decreased irritability scores in the buspirone group. ,,None,N/a,"Increased appetite, drowsiness, and fatigue in buspirone group. ",No serious AEs. Generally safe. ,n=6,,"""Buspirone may be considered for children with SIBs who have concomitant anxiety."" ",,,,,,,
Risperidone + NAC,Yes,Yes,"Ghanizadeh, Ahmad",,No conflicts of interest. ,"July 25, 2013",BioMed Central Psychiatry,Randomized Double-blind Placebo Controlled ,8 weeks,40,25 M: 15 F,3.5-16 y; mean: 7.9-8.8 y,"NAC: 1200 mg/d (In 2 divided doses) + risperidone: 0.5-3 mg/d (m: 0.76), or risperidone (m: 0.92) + placebo. ",Irritability,ABC- irritability subscale,The group treated with NAC had significant reductions in ABC irritability scores compared to placebo. ,Other core symptoms of ASD. ,"Other ABC-C subscales - Hyperactivity and noncompliance, Lethargy and social withdrawal, stereotypic behavior, and inappropriate speece",There were no differences between groups in changes in secondary outcome measures. ,"AEs were mild in severity and medication was well tolerated. The NAC treatment group experienced greater rates of daytime drowsiness, fatigue, constipation, and nervousness. ","One patient withdrew from the trial due to severe sedation. Otherwise, the AEs were mild. ",n=9; One patient in the NAC group withdrew due to AE.,Baseline demographics not reported. ,Risperidone was flexibly dosed based on efficacy and weight. ,Low risk - allocation based on a random number generator. ,"Low risk - ""NAC and placebo tablets were administered in the form of effervescent... The shape, size, taste, and color of NAC and placebo were identical."" ",,"Low risk - Patients, parents, and assessor were blinded to the treatment allocation. ",Low risk - All assessment scores reported for both groups. ,Low risk - Insignificant results reported. ,This study used a convenience sample of outpatients recruited from the Child and Adolescent Psychiatry Clinics associated with Shiraz University of Medical Sciences. 
Risperidone + NAC,Yes,yes,"Nikoo, Mohammadali",,No conflicts of interest. ,January 2015,Clinical Neuropharmacology,Randomized Double-blind Placebo Controlled ,10 weeks ,50,,4-12 y,"NAC: 600-900 mg/d (3 divided doses) + risperidone: 1-2 mg/d, or + placebo",Irritability,ABC-I subscale,The NAC treatment group experienced greater reduction in irritability scores than the placebo group. ,,,,,,n=10,Baseline characteristics were not significantly different in the participants.,,,,,,,,
Risperidone + Topiramate ,Yes (risperidone) No (topiramate),Yes (risperidone) No (topiramate),"Rezaei, Vala",10.1016/j.pnpbp.2010.07.005,,July 2010,Progress in Neuro-Psychopharmacology and Biological Psychiatry,Randomized Double-blind Placebo Controlled ,8 weeks ,40,27 M: 13 F,4-12 y ,Risperidone: 2 mg/d for pts under 40 kg and 3 mg/d for pt 40 kgo; Topirimate: 100 mg/d for pts under 30kg and 200 mg/d for pt 30 kgo,,ABC-C ,"The topiramate & risperidone treatment group had greater reductions in the irritability, hyperactivity/noncompliance, and stereotypy subscales. No significant group differences between placebo and topiramate in the lethargy/social withdrawal and inappropriate speech subscales.",,,,Somnolence and decreased appetite. ,,,,,Low risk,Low risk,Low risk,Low risk,Low risk,Low risk,
Risperidone v. Haloperidol,Yes (risperidone) No (Haloperidol),Yes (risperidone) No (Haloperidol),"Miral, Suha",,,"December 13, 2007",European Child & Adolescent Psychiatry,Randomized Double-blind Placebo Controlled  ,12 weeks ,30,,8-18 y,0.01-0.08 mg/kg/d,"Impulsivity, language skills, social relations.","ABC, PDD Scale scoress, Prolactine levels, RF-RLRS","""Risperidone was found to be more effective than haloperidol in treatment of behavioral symptoms, impulsivity, language skills, and impaired social relations�"" Risperidone: significant reduction in ABC and PDD scale scores, greater levels of prolactin, RF-RLRS decreased more in risperidone group. Haloperidol: greater increase in ALT",,,,Well tolerated,Generally safe,,,,,,,,,,
Sertraline,Yes,No,"Potter, Laura ",10.3389/fpsyt.2019.00810,No conflicts of interest. ,"November 6, 2019",Frontiers in psychiatry,Randomized Double-blind Placebo Controlled  ,6 months,58,46 M: 12 F,2-6 y,2.5 mg/d for participants 4yo; 5.0 mg/d for participants 4yo ,Language,"MSEL expressive language raw score, and age equivalent combined score",No significant group differences for primary outcomes. ,,"MSEL subset raw and age equivalent scores in visual reception, fine motor, and receptive language. CGI-I at EOT. PLS-5 auditory comprehension and expressive communication scores. PVET. VABS-II, ABC-C, PAS, SRS, and SPM-P",No group differences in any secondary outcomes. ,"Well tolerated with no group difference in AEs. Common side effects included upper respitory infection, diarrhea, and hyperactivity. ","One serious AE, dehydration secondary to viral infection led to hospitalization of one sertraline pt. ","n=13 (8 sertraline, 5 placebo)",7 Black; 11 Asian; 3 Other/unknown; 37 White,"""The trial drew subjects mainly from the northern California area, out of convenience. Thus, the study sample may not be representative of the greater population of children with ASD.""",Low risk - The UC Davis Investiagational Drug Services independently carried out randomization to sertraline or placebo.,"Low risk - ""Placebo formulated as a clear, colorless solution, and contained menthl to match both the appearance and smell of liquid sertraline.""","Placebo formulated as a clear, colorless solution, and contained menthl to match both the appearance and smell of liquid sertraline.",,,,
Sulforaphane ,,,"Singh, Kanwaljit",,The Johns Hopkins University has applied to patent this. Not a commercial product. ,"October 28, 2014",PNAS,Randomized Double-blind Placebo Controlled  ,27 weeks total (4 wk washout),44,100% M,13-27 y; Mean: 17 y,50-150 umol,Social behaviors. ,"Aberrant Behavior Checklist (ABC), Social Reponsiveness Scale (SRS), and Clinical Global Impression Improvement Scale (CGI-I)",Substantial improvements in ABC and SRS scores in the sulforaphane treatment group. ,,N/A,N/A,Well tolerated with limited side effects. ,"""Favorable safety profile"" and ""recognized low toxicity""",n=3,39 White; 2 Black; 1 Hispanic; 2 Asian,"Limitations: the study only tested males who were primarily caucasian. ""�responses to sulforaphane in this study appeared over several weeks. This finding suggests that sulforaphane may cause increases in gene transcription in multiple underperforming cell-signaling pathways.""",,,,,,,
Tetrahydrobiopterin (BH4),,,"Klaiman, Cheryl",,Funded by Biomarin Pharmaceuticals,"November 5, 2009",Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled ,16 weeks,46,38 M: 8 F,"3-7 y, Mean: 12 y",20 mg/kg/d,,Clinical Global Impressions- Improvent and Severity Scales (CGI-I and CGI-S),No differences in the CGI-I or CGI-S scores between the BH4 treatment group and the placebo group. ,"Social and language skills,  hyperactivity, movements. ","Preschool Language Scale (PLS-4), Social Responsiveness Scale (SLS), Aberrant Behavior Checklist (ABC), and Vineland Adaptive Behavior Scales (Vineland)","Significant improvements in social awareness, autism mannerisms, hyperactivity, and inappropriate speech in the BH4 treated group. ","Minimal and similar AEs in both groups. Common side effects included irritability, difficulty sleeping, changes in bowel habits, repetitive behavior, hyperactivity, and transient viral rash. ",No AEs in 39% of participants. One unanticipated serious adverse event in the placebo group. A participant developed new-onset seizures on the last day of the study. ,"n=4 (1 placebo, 3 BH4)",21 White; 14 Asian-Pacific Islander; 3 African American; 1 Hispanic; 7 Other,,,,,,,,
Topiramate,No,no,Rezaei,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TDCS and motor training,n/a,n/a,"Mahmoodifar, Elham",,No conflicts of interest. ,2020,,RCT,,18,,"6-14 y (mean: 10.17, SD: 2.75)",1.5 mA anodal tDCS over the left MI for 20 minutes before 10 motor training sessions,Balance,Movement Assessment Battery for Children-2 (MABC-2),The experiment group preformed better on the balance test of the MABC-2. ,,,,,,,,,,,,,,,
Transcranial direct current stimulation (tDCS),,,"Qui, Jiujun",10.1155/2021/6627507,No conflict of interest,June 2021,Neural Plasticity,RCT,3 weeks,40,30 M: 10 F,2-6 y,tDCS over the left dorsal lateral prefrontal cortex (DLPFC) 5x/week,,"CARS, ABC, RBS-R",CARS scores reducted significantly after real tDCS.,Sleep condition,CSHQ,tDCS treatment significantly reduced CSHQ scores and the general impression item in CARS.,Well tolerated,Generally safe,,,,,,,,,,
Transcranial magnetic stimulation (rTMS) with language therapy,n/a,n/a,"Darwish, Mohamed",,No conflicts of interest. ,June 2021,The Egyptian Journal of Otalaryngology,RCT,4 weeks,30,20 M: 10 F,3-10 y (mean: 5-6 y),"Once per week over the left frontal gyrus: low frequency of 1.0 Hz and 70% of the motor threshold, total 1800 pulses per day session with 20 trains with 90 pulses each ",Language process,CARS,Significant improvement in CARS in rTMS group. ,Language process,"Audiological evaluation (using pure tone audiometry and confirmatory evoked response audiometry); Language evaluation, using Arabic language test (assessment of eye contact, response to examiner and obey simple order, attention evaluation, and passive and active language assessment)","Significant improvement in eye contact, and response to examiner in rTMS group. Significant improvement in active expressive language in rTMS group. No between-group difference in passive vocabulary.",Rates and types of AEs were not reported,No safety data reported,None reported,Not reported,,,,,,High risk - No side effect data reported,High risk - Not all outcome data reported.,
Trofinetide,,,"Berry-Kravis, Elizabeth",,,May 2020,Pediatric Neurology,Randomized Double-blind Placebo Controlled ,,72,100% male,,30 or 70 mg/kg BID trofinetide or placebo,,,,,,,,,,,,,,,,,,
Valproate ,Yes,No,"Hellings, Jessica",,,,Journal of Child and Adolescent Psychopharmacology,Randomized Double-blind Placebo Controlled ,8 weeks,30,20 M: 10 F,6-20 y; Mean: 11.2 y,,Irritability,ABC-C irritability subscale,No treatment difference. ,,CGI-Improvement and OAS,No treatment difference. ,Increased appetite and skin rash. ,,,27 White; 2 Black; 1 Hispanic ,,,,,,,,
Vitamin D and Omega-3 Fatty Acids,,,"Mazahery, Hajar",,No conflicts of interest. ,"January 3, 2019",Journal of Autism & Developmental Disorders,Randomized Double-blind Placebo Controlled  ,1 year ,117,100 M: 17 F,2.5-8 y; Mean= 5.2y (SD: 1.4),2000 IU Vitamin D3; 722mg Omega 3- docosahexaenoic acid; both; or placebo ,Social responsiveness and sensory processing.,Social Responsiveness Scale (SRS) and Sensory Processing Measures (SPM),"""Omega-3 LCPUFA with and without vitamin D may improve some core symptoms of ASD."" OM conjunct VIDOM showed greater scores than other groups.Trends for greater improvements; Vit D3: SRS-social communicative functioning, SPM-taste/smell; Omega 3: SRS-Total, SPM-balance/motion. ",,none ,n/a,Well tolerated with minimal side effects. ,"6 allergic reactions: rash, facial pimple, and red ear. ",n=34,57 NZ European; 15 Maori; 13 Pacific Islander; 13 Asian; 18 Others,,,,,,,,
Venlafaxine + clonazepam and/or zuclopenthixol,yes: clonazepam and zuclopenthixol,yes: clonazepam,"Carminati, Giuliana",10.1016/j.pnpbp.2015.09.002,,September 2015,Progress in Neuropsychopharmacology & Biological Psychiatry,RCT,8 weeks,13,,,18.75 mg/d venlafaxine,Irritability and hyperactivity/noncompliance,"ABC, BPI",,Global improvement,,,,,,,,,,,,,,
Vitamin D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vasopressin (intranasal),n/a,n/a,"Parker, Karen",10.1126/scitranslmed.aau7356.,"Janssen Pharmaceuticals, Syneos Health, Saniona, Vista Point Capital, Katana Pharmaceuticals, Anatomics, Ginex Inc., Trigemina Inc. ",May 2019,Science Translational Medicine,RCT,4 weeks,30,25 M: 25 F,6-12 y (mean: 9.14-9.86 y),6-9.5 y: max: 12 IU BID; 9.6-12.9 y: 16 IU BID,Social abilities,"SRS-2, SCI, RRB",The AVP treatment group showed greater improvement in social abilities as shown by scores on SRS-2 and CGI-I scores. SRS-2 scores showed greater improvement in the participants with higher pretreatment AVP concentrations. ,"Social cognition improvement, anxiety, and ability to perceive others' intentions or emotions","CGI-S, CGI-I, RBS-R, SCAS, RMET, FERT, NEPSY assessment","AVP treatment reduced anxiety symptoms. Treatment effect was larger in participants with the highest pretreatment AVP concentrations. RBS-R and RRB subscale of SRS-2 scores did not improve significantly overall, but scores did improve in participants with the highest pretreatment AVP concentrations. AVP treatment also enhanced theory of mind abilities and increased facial emotion recognition abilities (FERT and RMET scores). ",Well tolerated with minimal side effects,Generally safe,n=0,"19 white, 11 ""other""",,high risk - randomization was performed by an unblinded investigator using a machine-generated treatment schedule. ,Low risk - 25 mL of AVP and placebo placed in identical bottles and indistinguishable to the research team,Low risk - Outcome assessors were blinded,Low risk - Participants and clinicians were blinded. ,Low risk - All outcome data reported in detail,Low risk - All outcome data reported,
Propentofylline + risperidone,,,"Behmanesh, Helen",DOI:�10.1097/WNF.0000000000000368,,November 2019,Clinical Neuropharmacology,RCT,10 weeks,48,,,,Irritability,ABC-C irritability,Significant time by treatment interaction on ABC-C irritability scores.,ASD severity and behavioral disruptions,ABC-C and CARS,Greater improvements in CARS scores with propentofylline treatment. No difference in treatment effect on all other ABC-C subscales. ,,,,,,,,,,,,
Prednisolone + risperidone,yes,yes,"Malekfarhad, Malek",https://journals.lww.com/clinicalneuropharm/Abstract/2020/03000/Prednisolone_as_Adjunctive_Treatment_to.2.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pregnenolone + risperidone,,,"Ayatollahi, Arghavan",https://journals.lww.com/clinicalneuropharm/Abstract/2020/09000/Does_Pregnenolone_Adjunct_to_Risperidone.3.aspx,,2020,Clinical Neuropharmacology,RCT,,64,,,,Irritability,ABC-C irritability,Greater improvement in ABC-C irritability scores in the treatment group. ,,ABC-C other subscales,Greater improvement in stereotypy and hyperactivity subscales of the ABC-C in the treatment group. No changes in lethargy and inappropriate speech scores. ,No difference in frequency of side effects between groups,No difference in severity of side effects between treatment groups,"n=5 (2 pregnenolone, 3 placebo)",,,,,,,,,
